Size-minimized CAS9 proteins for use in gene editing systems

Compact CRISPR Cas9 proteins with targeted deletions enhance delivery and expression of gene editors, addressing size limitations in existing systems and improving in vivo delivery efficiency.

WO2026236221A1PCT designated stage Publication Date: 2026-11-12THE BROAD INST INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026700
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The large size of CRISPR Cas9-based gene editing systems, such as base editors and prime editors, poses challenges for efficient in vivo delivery via vectors like AAVs, LNPs, and eVLPs, as they exceed packaging limits and compromise expression and delivery efficiency.

Method used

Development of compact versions of CRISPR Cas9 proteins (SpCas9 and SauriCas9) with specific amino acid deletions, enabling smaller gene editors that improve packaging efficiency and expression levels using AAVs, LNPs, or eVLPs.

Benefits of technology

The engineered Cas9 proteins facilitate improved delivery and expression of gene editors, maintaining their effectiveness and versatility for genome targeting in humans and other organisms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026700_12112026_PF_FP_ABST
    Figure US2026026700_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure introduces smaller, effective versions of gene editing systems, including prime and base editors, achieved by engineering compact forms of CRISPR Cas9 proteins (e.g., Streptococcus pyogenes Cas9 ("SpCas9") and Staphylococcus auricularis Cas9 ("SauriCas9")). These compact proteins incorporate size-reducing deletions, resulting in smaller gene editor fusion proteins. The compactness improves packaging efficiency and expression levels when delivered using systems, such as adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), or engineered virus-like particles (eVLPs). The disclosure encompasses compositions and methods related to these compact gene editing systems, including isolated fusion proteins with reduced-size engineered CRISPR Cas9 proteins, nucleic acid molecules encoding them, and delivery systems that utilize the compact gene editing systems and associated guide RNAs for gene editing applications.
Need to check novelty before this filing date? Find Prior Art

Description

SIZE-MINIMIZED CAS9 PROTEINS FOR USE IN GENE EDITING SYSTEMSRELATED APPLICATIONS

[0001] This application claims priority under 35 U. S. C. § 119(e) to U. S. Provisional Application, U. S. S. N. 63 / 801,072, filed May 6, 2025, which is incorporated herein by reference.GOVERNMENT SUPPORT

[0002] This invention was made with government support under HL 152960 and GM 118062 awarded by National Institutes of Health. The government has certain rights in the invention.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (B119570213WO00-SEQ-TNG.xml; Size: 459,377 bytes; and Date of Creation: April 30, 2026) are herein incorporated by reference in their entirety.BACKGROUND

[0004] Developing smaller, compact versions of CRISPR Cas9 proteins is an important goal for enhancing the effective delivery of CRISPR-based gene editing technologies, particularly base editors and prime editors, which are built from CRISPR Cas9 fusion proteins and have high molecular weights. For example, base editors — which comprise at least a CRISPR Cas9 protein and a deaminase — can be upwards of 200 kDa or more. Prime editors — which comprise at least a CRISPR Cas9 protein and a reverse transcriptase — can be upwards of 230 kDa or more.

[0005] In a particular example, a PE6c prime editor can have a molecular weight of approximately 225 kDa and is encoded by a gene that spans nearly 6000 nucleotides, not counting any regulatory regions and / or sequences encoding guide RNAs required for their function. In another example, cytosine base editors also face packaging inefficiencies due to the additional requirement for a uracil glycosylase inhibitor (UGI) domain which can add up to another 20 kDa or so to base editor fusion proteins. In addition, constructs that encode such base editors and prime editors often require the incorporation of tissue-specific enhancers and promoters, which are critical for directing gene expression to targeted tissues and enhancing the safety profile of therapies, but which add even more size to such systems.1 / 155B1195.70213WO00#15140132v3

[0006] The considerable size of these gene editing systems presents challenges for efficient in vivo delivery via various vectors, including adeno-associated viruses (AAVs), lipid nanoparticles (LNPs), and engineered virus-like particles (eVLPs). This issue is particularly pronounced with AAVs, which have a packaging capacity of approximately 4,900 base pairs. As a result, larger genome editors cannot be effectively co-packaged with essential components, such as multiple guide RNAs, without compromising their expression and delivery efficiency. Therefore, there is a pressing need for smaller and more compact versions of gene editing systems that maintain their effectiveness.SUMMARY

[0007] The present disclosure relates, in part, to the discovery that smaller but effective versions of prime editors and base editors with improved delivery characteristics can be obtained by engineering compact versions of CRISPR Cas9 proteins (e.g., Streptococcus pyogenes Cas9 (“SpCas9”) and Staphylococcus auricularis Cas9 (“SauriCas9”)). The compact versions of the CRISPR Cas9 proteins (e.g., SpCas9 and SauriCas9) comprise one or more size- decreasing deletions which result in smaller-sized gene editors (e.g. base editor and prime editors) in which they are incorporated. By leveraging the smaller size of these engineered Cas9 proteins, there is potential for improved packaging efficiency and higher expression levels when using an in vivo delivery system such as an adeno-associated virus vector (AAVs), lipid nanoparticles (LNPs), or engineered virus-like particles (eVLPs).Together, compact versions of prime editors and base editors which are based on SpCas9 — which recognizes the NGG protospacer adjacent motif (PAM) — or SauriCas9 — which targets the NNGG PAM — provide versatile genome targeting capabilities in humans and other organisms. The engineering strategies described in this disclosure with regard to SpCas9 and SauriCas9 may also be applicable to other Cas9 orthologs, unlocking new possibilities for CRISPR-based gene editing applications, including for base editors and prime editors.

[0008] The present disclosure outlines a minimized Streptococcus pyogenes Cas9 (SpCas9) protein that features deletions of specific amino acid residues, including but not limited to, residues 172-176, 172-182, 173-177, 174-178, 175-179, 176-180, 177-181, 172-182, 174- 188, 209-214, 211-216, 213-218, 646-657, 646-649, 647-650, 648-651, 668-675, 670-677, 671-677, 672-679, 673-680, 818-830, or 819-831, relative to a SpCas9 protein with a specific amino acid sequence (SEQ ID NO: 10). This minimized SpCas9 protein can also have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% sequence identity with the amino acid sequence of SEQ ID NO: 10 and at 2 / 155B1195.70213WO00#15140132v3least one deletion at residues 172-176, 172-182, 173-177, 174-178, 175-179, 176-180, 177-181, 172-182, 174-188, 209-214, 211-216, 213-218, 646-657, 646-649, 647-650, 648-651, 668-675, 670-677, 671-677, 672-679, 673-680, 818-830, or 819-831, or in the corresponding residue of a homolog of SEQ ID NO: 10.

[0009] Additionally, disclosure also includes fusion proteins comprising a minimized SpCas9 protein and a nucleobase modifying enzyme, which may be a reverse transcriptase or a deaminase, such as a cytidine deaminase or an adenosine deaminase. Furthermore, the prime editor may comprise a Cas9 domain having an amino acid sequence with at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to specified SEQ ID NOs: 20-174.

[0010] Complexes are described that consist of the fusion protein and one or more guide RNAs, including engineered pegRNAs. Various compositions are also provided that comprise the minimized SpCas9 protein, fusion proteins, base editors, prime editors, and complexes, along with guide RNAs. The polynucleotide encoding these components and vectors are also detailed. The fusion proteins may be split, containing N-terminal and C-terminal portions, with the N-terminal portion including an N-intein.

[0011] Finally, pharmaceutical compositions incorporating these minimized Cas9 proteins, fusion proteins, base editors, prime editors, polynucleotides, and vectors are discussed, alongside methods for gene editing, base editing, and prime editing involving these components.

[0012] The present disclosure also describes minimized Staphylococcus auricularis Cas9 (referred to as “SauriCas9”) proteins that feature deletions of specific amino acid residues. These deletions may include residues 1-3, 1-6, 125-132, 125-140, 128-135, 322-329, 725-766, 743-750, 1046-1061, or 1051-1061, relative to a SauriCas9 protein with a defined amino acid sequence (e.g., SEQ ID NO: 11). The minimized SauriCas9 protein can also exhibit at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 11 and have at least one deletion at residues 1-3, 1-6, 125-132, 125-140, 128-135, 322-329, 725-766, 743-750, 1046-1061, or 1051-1061, or in corresponding residues of a homolog of SEQ ID NO: 11. In some embodiments, the minimized SauriCas9 protein may specifically comprise deletions of residues such as 1-3, 1-6, 125-132, 125-140, 128-135, and others, as outlined above. Additionally, the disclosure encompasses fusion proteins that consist of a minimized SauriCas9 protein and a nucleobase modifying enzyme. This enzyme may either be a reverse transcriptase or a deaminase; in particular, the deaminase could be a cytidine deaminase or an adenosine deaminase.3 / 155B1195.70213WO00#15140132v3

[0013] Moreover, the disclosure includes base editors and prime editors that comprise a Cas9 domain having an amino acid sequence with at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to specified SEQ ID NOs: 175-194. It provides complexes that include the aforementioned SauriCas9 proteins or fusion proteins along with one or more guide RNAs. Compositions are provided that comprise the minimized SauriCas9 protein, fusion proteins, base editors, prime editors, and complexes, all in conjunction with guide RNAs.

[0014] Furthermore, the disclosure addresses polynucleotides that encode the minimized SauriCas9 proteins, fusion proteins, base editors, or complexes, as well as vectors that incorporate these polynucleotides. The fusion proteins may be structured as split fusion proteins, consisting of an N-terminal portion and a C-terminal portion, where the N-terminal portion includes an N-intein and the C-terminal portion includes a C-intein.

[0015] Lastly, the present disclosure presents pharmaceutical compositions that incorporate the minimized SauriCas9 proteins, fusion proteins, base editors, polynucleotides, or vectors along with a pharmaceutically acceptable excipient. It describes cells that contain any of the mentioned components and kits that include these elements as well. Methods for gene editing, base editing, and prime editing are also detailed, wherein a target nucleic acid sequence is contacted with a fusion protein and a guide RNA or pegRNA.

[0016] Finally, the use of the herein disclosed fusion proteins, complexes, and compositions in the manufacture of a medicament is particularly significant for targeted gene editing.BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0018] FIGs. 1A-1C show adeno-associated virus is a promising delivery option for prime editors. Adeno-associated vectors (AAVs) are clinically validated and FDA approved, and have diverse serotypes which enable targeting to different tissues in vivo. However, they have a strict 4.9 kb cargo packaging limit. As shown in FIG. 1B, in prime editing, splitting the prime editor into two AAV genomes enables efficient editing in vivo.

[0019] FIGs. 2A-2B show size constraints for prime editor delivery in 2-AAV and 1-AAV systems.4 / 155B1195.70213WO00#15140132v3

[0020] FIGs. 3A-3C show prediction of functional SpCas9 deletion variants using AlphaFold2. “MISER” refers to an experimentally validated dataset of minimized SpCas9 DNA binders as described in Shams, Savage, et al., Nature Comms, 2021.

[0021] FIGs. 4A-4H show that small Cas9 deletions are tolerated in PE6c.

[0022] FIG. 5 shows activities of PE6c prime editors with combinations of small Cas9 deletions.

[0023] FIGs. 6A-6B show that the SpCas9 REC2 domain is not essential for catalytic activity.

[0024] FIG. 7 shows functional roles of particular SpCas9 REC2 domain residues.

[0025] FIGs. 8A-8B show that SpCas9 REC2 partial domain deletions are not functional.

[0026] FIG. 9 shows the use of computational design tools to minimize the Cas9 REC2 domain.

[0027] FIG. 10 shows activity of S. auricularis Cas9 cytosine base editors with internal truncations.

[0028] FIGs. 11A-11B show that AlphaFold2 predicts functional size-minimized cytosine base editors. Deletion variants that fold more closely to the wild-type structure may have a higher probability of functioning as gene editors.

[0029] FIGs. 12A-12B shows the results on an initial deletion screen that identifies five small regions in Cas9 that tolerate deletion in prime editors.

[0030] FIG. 13 shows the results of optimal single-deletions across five Cas9 regions.DEFINITIONS

[0031] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them unless specified otherwise.Adenosine deaminase

[0032] As used herein, the term “adenosine deaminase” or “adenosine deaminase domain” refers to a protein or enzyme that catalyzes a deamination reaction of an adenosine (or5 / 155B1195.70213WO00#15140132v3adenine). The terms are used interchangeably. In certain embodiments, the disclosure provides nucleobase editor fusion proteins comprising one or more adenosine deaminase domains (e.g., fused to a napDNAbp such as a Cas9 protein). For instance, an adenosine deaminase domain may comprise a heterodimer of a first adenosine deaminase and a second deaminase domain, connected by a linker. Adenosine deaminases (e.g., engineered adenosine deaminases or evolved adenosine deaminases) provided herein may be enzymes that convert adenine (A) to inosine (I) in DNA or RNA. Such adenosine deaminases can lead to an A: T to G: C base pair conversion. In some embodiments, the deaminase is a variant of a naturally-occurring deaminase from an organism (e.g., bacteria, such as E. coli). In some embodiments, the deaminase does not occur in nature. For example, in some embodiments, the deaminase is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a naturally occurring deaminase.

[0033] In some embodiments, the adenosine deaminase is derived from a bacterium, such as, E. coli, S. aureus, S. typhi, S. putrefaciens, H. influenzae, C. jejuni, or C. crescentus. In some embodiments, the adenosine deaminase is a TadA deaminase. In some embodiments, the TadA deaminase is an E. coli TadA deaminase (ecTadA). In some embodiments, the TadA deaminase is a truncated E. coli TadA deaminase. For example, the truncated ecTadA may be missing one or more N-terminal amino acids relative to a full-length ecTadA. In some embodiments, the truncated ecTadA may be missing 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the truncated ecTadA may be missing 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 C-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the ecTadA deaminase does not comprise an N-terminal methionine. In some embodiments, the adenosine deaminase comprises ecTadA(8e) (z.e., as used in the base editor ABE8e) as described further herein. Adenosine deaminases are further described, for example, in International Patent Application Publication No. WO 2018 / 027078, published February 8, 2018, which is incorporated herein by reference.ABE-targetable mutation

[0034] As used herein, the term “ABE-targetable” (or “ABE-correctable”) mutation is a mutation which is capable of being targeted by an adenine base editor complexed with an appropriately designed guide RNA to result in a desired edit to correct a C> T or G> A mutation at a specified nucleotide residue position relative to a wildtype nucleotide sequence. Thus, an ABE-targetable mutation is either T: A base pair installed in place of a wildtype C: G6 / 155B1195.70213WO00#15140132v3base pair, or an A: T base pair installed in place of a wildtype G: C base pair. As a result of the edit by the ABE, the T: A pair is converted back to a C: G base pair, and the A: T pair is converted back to the G: C pair. The person having ordinary skill in the art will appreciate that an AB E-targetable mutation further requires that the target sequence comprising the mutation to be corrected comprises a suitable PAM (protospacer adjacent motif) sequence that is recognized and bound by the particular napDNAbp domain utilized as part of the ABE editor complex, and an editing window comprising the mutation to be corrected.Base editing

[0035] ‘ ‘Base editing” refers to a genome editing technology that involves the conversion of a specific nucleic acid base into another at a targeted genomic locus. In certain embodiments, this can be achieved without requiring double- stranded DNA breaks (DSB), or single stranded breaks (z.e., nicking). Many other genome editing techniques, including CRISPR-based systems, begin with the introduction of a DSB at a locus of interest. Subsequently, cellular DNA repair enzymes mend the break, commonly resulting in random insertions or deletions (indels) of bases at the site of the DSB. However, when the introduction or correction of a point mutation at a target locus is desired rather than stochastic disruption of the entire gene, these genome editing techniques are unsuitable, as correction rates are low (e.g., typically 0.1% to 5%), with the major genome editing products being indels. In order to increase the efficiency of gene correction without simultaneously introducing random indels, the CRISPR system is modified to directly convert one DNA base into another without DSB formation. See, Komor, A. C., et al., Programmable editing of a target base in genomic DNA without double- stranded DNA cleavage. Nature 533, 420-424 (2016), the entire contents of which is incorporated by reference herein. In some embodiments, base editing is accomplished using a fusion protein comprising a deaminase and napDNAbp (e.g., a Cas9 protein).

[0036] In principle, there are 12 possible base-to-base changes that may occur via individual or sequential use of transition (i.e., a purine-to-purine change or pyrimidine-to-pyrimidine change) or transversion (i.e., a purine-to-pyrimidine or pyrimidine-to-purine) editors. These include transition base editors such as the cytosine base editor (“CBE”), also known as a C-to-T base editor (or “CTBE”). This type of editor converts a C: G Watson-Crick nucleobase pair to a T: A Watson-Crick nucleobase pair. Because the corresponding Watson-Crick paired bases are also interchanged as a result of the conversion, this category of base editor may also be referred to as a guanine base editor (“GBE”) or G-to-A base editor (or “GABE”). Other7 / 155B1195.70213WO00#15140132v3transition base editors include the adenine base editor (or “ABE”), also known as an A-to-G base editor (“AGBE”). This type of editor converts an A: T Watson-Crick nucleobase pair to a G: C Watson-Crick nucleobase pair. Because the corresponding Watson-Crick paired bases are also interchanged as a result of the conversion, this category of base editor may also be referred to as a thymine base editor (or “TBE”) or T-to-G base editor (“TGBE”).Base editors

[0037] The terms “base editor (BE)” and “nucleobase editor,” which are used interchangeably herein, refer to an agent comprising a polypeptide that is capable of making a modification to a base (e.g., A, T, C, G, or U) within a nucleic acid sequence (e.g., DNA or RNA) that converts one base to another (e.g., A to G, A to C, A to T, C to T, C to G, C to A, G to A, G to C, G to T, T to A, T to C, or T to G). In some embodiments, the base editor is capable of deaminating a base within a nucleic acid, such as a base within a DNA molecule. In some embodiments, a base editor is an adenine base editor. In the case of an adenine base editor, the base editor is capable of deaminating an adenine (A) in DNA. Such base editors may include a nucleic acid programmable DNA binding protein (napDNAbp) fused to an adenosine deaminase. Some base editors include CRISPR-mediated fusion proteins that are utilized in the base editing methods described herein. In some embodiments, the base editor comprises a Cas9 protein fused to a deaminase that binds a nucleic acid in a guide RNA-programmed manner via the formation of an R-loop, but does not cleave the nucleic acid.

[0038] In some embodiments, a base editor is a macromolecule or macromolecular complex that results primarily (e.g., more than 80%, more than 85%, more than 90%, more than 95%, more than 99%, more than 99.9%, or 100%) in the conversion of a nucleobase in a polynucleotide sequence into another nucleobase (i.e., a transition or transversion) using a combination of 1) a nucleotide-, nucleoside-, or nucleobase-modifying enzyme, and 2) a nucleic acid binding protein that can be programmed to bind to a specific nucleic acid sequence.

[0039] In some embodiments, the base editor comprises a DNA binding domain (e.g., a programmable DNA binding domain, such as a Cas9 protein) that directs it to a target sequence. In some embodiments, the base editor comprises a nucleobase modification domain fused to a programmable DNA binding domain (e.g., a Cas9 protein). The terms “nucleobase modifying enzyme” and “nucleobase modification domain,” which are used interchangeably herein, refer to an enzyme that can modify a nucleobase and convert one nucleobase to another (e.g., a deaminase, such as a cytidine deaminase or an adenosine8 / 155B1195.70213WO00#15140132v3deaminase). In some embodiments, A to G editing is carried out by a deaminase, e.g., an adenosine deaminase.

[0040] In some embodiments, a base editor converts an A to a G. In some embodiments, the base editor comprises an adenine deaminase. An “adenine deaminase” is an enzyme involved in purine metabolism. It is needed for the breakdown of adenosine from food and for the turnover of nucleic acids in tissues. Its primary function in humans is the development and maintenance of the immune system. An adenine deaminase catalyzes hydrolytic deamination of adenosine (forming inosine, which base pairs as G) in the context of DNA. There are no known natural adenine deaminases that act on DNA. Instead, known adenine deaminase enzymes only act on RNA (tRNA or mRNA). Evolved deoxy adenosine deaminase enzymes that accept DNA substrates and deaminate dA to deoxyinosine have been described, e.g., in International Patent Application No. PCT / US2017 / 045381, filed August 3, 2017, which published as WO 2018 / 027078, International Patent Application No. PCT / US2019 / 033848, which published as WO 2019 / 226953, International Patent Application No PCT / US2019 / 033848, filed May 23, 2019, which published as WO 2019226953, and International Patent Application No. PCT / US2020 / 028568, filed April 17, 2020, which published as WO 2020214842; each of which is incorporated herein by reference.

[0041] Exemplary adenine base editors are also described in Rees & Liu, “Base editing: precision chemistry on the genome and transcriptome of living cells,” Nat. Rev. Genet.2018;19(12):770-788; as well as U. S. Patent Application Publication No. 2018 / 0073012, published March 15, 2018, which issued as U. S. Patent No. 10,113,163 on October 30, 2018; U. S. Patent Application Publication No. 2017 / 0121693, published May 4, 2017, which issued as U. S. Patent No. 10,167,457 on January 1, 2019; PCT Application Publication No. WO 2017 / 070633, published April 27, 2017; U. S. Patent Application Publication No.2015 / 0166980, published June 18, 2015; U. S. Patent No. 9,840,699, issued December 12, 2017; and U. S. Patent No. 10,077,453, issued September 18, 2018, each of which is incorporated herein by reference.Cas9

[0042] The term “Cas9” or “Cas9 nuclease” refers to an RNA-guided protein comprising a Cas9 domain, or a fragment thereof (e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and / or the gRNA binding domain of Cas9). A “Cas9 domain,” as used herein, is a protein fragment comprising an active or fully or partly inactive cleavage domain of Cas9 and / or the gRNA binding domain of Cas9. A “Cas9 protein” is a full length9 / 155B1195.70213WO00#15140132v3Cas9 protein. A Cas9 protein is also referred to sometimes as a casnl protein or a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)-associated protein. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (me), and a Cas9 domain. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9 / crRNA / tracrRNA endonucleolytically cleaves a linear or circular dsDNA target complementary to the spacer. The strand in the target DNA not complementary to crRNA is first cut endonucleolytically, then trimmed 3 '-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gRNA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the contents of which are incorporated herein by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 protein sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U. S. A.98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 proteins and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 proteins and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems”10 / 155B1195.70213WO00#15140132v3(2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 protein comprises one or more mutations that partially impair or inactivate the DNA cleavage domain.

[0043] A nuclease-inactivated Cas9 domain may interchangeably be referred to as a “dCas9” protein (for nuclease-“dead” Cas9). Methods for generating a Cas9 domain (or a fragment thereof) having an inactive DNA cleavage domain are known (see, e.g., Jinek et al., Science.337:816-821(2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell. 28;152(5): 1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvCl subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC 1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi etal., Cell. 28;152(5): 1173-83 (2013)). In some embodiments, a Cas9 protein comprises one or more mutations to inactivate the nuclease activity of only one of the HNH subdomain or the RuvC 1 subdomain.

[0044] In some embodiments, proteins comprising fragments of a Cas9 protein are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9, or fragments thereof, are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example, a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, at least about 99.8% identical, or at least about 99.9% identical to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 10). In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more amino acid changes compared to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 10). In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99%11 / 155B1195.70213WO00#15140132v3identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 10). In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% Fusion protein

[0045] The term “fusion protein” as used herein refers to a hybrid polypeptide that comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein, thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a Cas9 protein fused to a deaminase (i.e., a base editor). Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2012)), the entire contents of which is incorporated herein by reference.Cas9 - Streptococcus pyogenes Cas9 (“SpCas9”)

[0046] The term Streptococcus pyogenes Cas9 (“SpCas9”) refers to a Cas9 that naturally occurs in Streptococcus pyogenes and which has the following 1368 (160 kDa) amino acid sequence (SEQ ID NO: 10) (see UniProt Protein Sequence TYL01049.1 and Nucleotide Sequence SJLL01000001).MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKLKGLGNTDRHGIKKNLIGALLFDSGE TAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHE RHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKVDLRLIYLALAHMIKFRGHFLIEG DLNPDNSDVDKLFIQLVQTYNQLFEENPINASRVDAKAILSARLSKSRRLENLIAQLP GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYA DLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLAKLNREDLLRKQR TFDNGSIPYQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA WMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD12 / 155B1195.70213WO00#15140132v3SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSDILKEYPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDK NRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKVGFIK RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVRVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV AKVEKGKSKKLKSVKELLGITIMERSSFEKDPIDFLEAKGYKEVRKDLIIKLPKYSLFE LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 10).Cas9 - Staphylococcus auricularis Cas9 (“SauriCas9”)

[0047] The term Staphylococcus auricularis Cas9 (“SauriCas9”) refers to a Cas9 that naturally occurs in Staphylococcus auricularis, and which has the following 1061 (117 kDa) amino acid sequence (SEQ ID NO: 11) (see NCBI Reference Sequence: WP_107392933.1). MQENQQKQNY ILGLDIGITS VGYGLIDSKT REVIDAGVRL FPEADSENNS NRRSKRGARR LKRRRIHRLN RVKDLLADYQ MIDLNNVPKS TDPYTIRVKG LREPLTKEEF AIALLHIAKR RGLHNISVSM GDEEQDNELS TKQQLQKNAQ QLQDKYVCEL QLERLTNINK VRGEKNRFKT EDFVKEVKQL CETQRQYHNI DDQFIQQYID LVSTRREYFE GPGNGSPYGW DGDLLKWYEK LMGRCTYFPE ELRSVKYAYS ADLFNALNDL NNLVVTRDDN PKLEYYEKYH IIENVFKQKK NPTLKQIAKE IGVQDYDIRG YRITKSGKPQ FTSFKLYHDL KNIFEQAKYL EDVEMLDEIA KILTIYQDEI SIKKALDQLP ELLTESEKSQ IAQLTGYTGT HRLSLKCIHI VIDELWESPE NQMEIFTRLN LKPKKVEMSE IDSIPTTLVD EFILSPWKR AFIQSIKVIN AVINRFGLPE DIIIELAREK NSKDRRKFIN KLQKQNEATR KKIEQLLAKY GNTNAKYMIE KIKLHDMQEG KCLYSLEAIP LEDLLSNPTH YEVDHIIPRS VSFDNSLNNK VLVKQSENSK KGNRTPYQYL SSNESKISYN QFKQHILNLS KAKDRISKKK RDMLLEERDI NKFEVQKEFI NRNLVDTRYA TRELSNLLKT YFSTHDYAVK VKTINGGFTN HLRKVWDFKK HRNHGYKHHA EDALVIANAD FLFKTHKALR RTDKILEQPG LEVNDTTVKV DTEEKYQELF ETPKQVKNIK QFRDFKYSHR VDKKPNRQLI NDTLYSTREI DGETYWQTL KDLYAKDNEK VKKLFTERPQ KILMYQHDPK TFEKLMTILN QYAEAKNPLA AYYEDKGEYV TKYAKKGNGP AIHKIKYIDK KLGSYLDVSN KYPETQNKLV KLSLKSFRFD IYKCEQGYKM VSIGYLDVLK KDNYYYIPKD KYEAEKQKKK13 / 155B1195.70213WO00#15140132v3IKESDLFVGS FYYNDLIMYE DELFRVIGVN SDINNLVELN MVDITYKDFC EVNNVTGEKR IKKTIGKRVV LIEKYTTDIL GNLYKTPLPK KPQLIFKRGE L ( SEQ ID NO: 11).Guide RNA (“gRNA”)

[0048] As used herein, the term “guide RNA” is a particular type of guide nucleic acid which is commonly associated with a Cas protein (e.g., a Cas9 protein), directing the Cas protein to a specific sequence in a DNA molecule that includes complementarity to the protospacer sequence of the guide RNA. For example, a gRNA may direct a Cas protein (e.g., as part of a base editor) to a target site in a gene. However, this term also embraces the equivalent guide nucleic acid molecules that associate with Cas protein equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or recombinant), and which otherwise program the Cas protein equivalent to localize to a specific target nucleotide sequence. The Cas protein equivalents may include other napDNAbps from any type of CRISPR system (e.g., type II, V, VI), including Cpfl (a type-V CRISPR-Cas system), C2cl (a type V CRISPR-Cas system), C2c2 (a type VI CRISPR-Cas system), and C2c3 (a type V CRISPR-Cas system). Further Cas-equivalents are described in Makarova et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” Science 2016; 353(6299), which is incorporated herein by reference.Exemplary sequences and structures of guide RNAs are provided herein.

[0049] Functionally, guide RNAs associate with a Cas protein, directing (or programming) the Cas protein to a specific sequence in a DNA molecule that includes a sequence complementary to the protospacer sequence for the guide RNA. A gRNA is a component of the CRISPR / Cas system. The sequence specificity of a Cas DNA-binding protein is determined by gRNAs, which have nucleotide base-pairing complementarity to target DNA sequences. The native gRNA comprises a 20 nucleotide (nt) spacer, which specifies the DNA sequence to be targeted, and is immediately followed by an 80 nt scaffold sequence, which associates the gRNA with the Cas protein. In some embodiments, an spacer of the present disclosure has a length of 15 to 100 nucleotides, or more. For example, an spacer may have a length of 15 to 90, 15 to 85, 15 to 80, 15 to 75, 15 to 70, 15 to 65, 15 to 60, 15 to 55, 15 to 50, 15 to 45, 15 to 40, 15 to 35, 15 to 30, or 15 to 20 nucleotides. In some embodiments, the spacer is 20 nucleotides long. For example, the spacer may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides long. At least a portion of the target DNA sequence is complementary to the spacer of the gRNA. For a Cas protein to successfully bind to the DNA target sequence, a region of the target sequence is complementary to the spacer of the gRNA14 / 155B1195.70213WO00#15140132v3sequence and is immediately followed by the correct protospacer adjacent motif (PAM) sequence. In some embodiments, a spacer is 100% complementary to its target sequence. In some embodiments, the spacer sequence is less than 100% complementary to its target sequence and is, thus, considered to be partially complementary to its target sequence. For example, a targeting sequence may be 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% complementary to its target sequence. In some embodiments, the protospacer of template DNA or target DNA may differ from a complementary region of a gRNA by 1, 2, 3, 4, or 5 nucleotides.

[0050] In some embodiments, the guide RNA is about 15-120 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence. In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 nucleotides long. In some embodiments, the guide RNA comprises a sequence of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more contiguous nucleotides that is complementary to a target sequence. Sequence complementarity refers to distinct interactions between adenine and thymine (DNA) or uracil (RNA), and between guanine and cytosine. In any of the guide RNA sequences provided herein, thymines and uracils may be used interchangeably, and a person of ordinary skill in the art will appreciate that the sequences comprise uracils because they are RNA.

[0051] In some embodiments, the term “guide RNA” includes prime editing guide RNAs (pegRNAs) and / or engineered prime editing guide RNAs (epegRNAs), which are further defined herein.Homolog

[0052] The term “homolog” or “homologous protein” refers to a protein from a different species that shares a common evolutionary ancestor, and therefore some amount of sequence identity, with a first protein. In some embodiments, the sequence of a homolog is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a first protein. In some embodiments, the sequence of a homolog is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%,15 / 155B1195.70213WO00#15140132v3at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a Cas9 protein of SEQ ID NO: 10 or 11.Linker

[0053] The term “linker,” as used herein, refers to a molecule linking two other molecules or moieties. The linker can be an amino acid sequence in the case of a linker joining two components of a fusion protein. For example, a napDNAbp (e.g., a Cas9 protein) can be fused to a deaminase (e.g., an adenosine deaminase) by an amino acid linker sequence. The linker can also be a nucleotide sequence in the case of joining two nucleotide sequences together (e.g., in a gRNA). In other embodiments, the linker is a non-peptide linker. In some embodiments, the linker is an organic molecule, group, polymer (e.g., a non-natural polymer), or chemical moiety. In some embodiments, the linker is 5-200 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. In some embodiments, the linker is 5-200 nucleotides in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 nucleotides in length. Longer or shorter linkers are also contemplated.napDNAbp

[0054] As used herein, the term “nucleic acid programmable DNA binding protein” or “napDNAbp,” of which Cas proteins such as Cas9 and variants thereof are examples, refers to a protein that uses RNA: DNA hybridization to target and bind to specific sequences in a DNA molecule. Each napDNAbp is associated with at least one guide nucleic acid (e.g., guide RNA), which localizes the napDNAbp to a DNA sequence that comprises a DNA strand (i.e., a target strand) that is complementary to the guide nucleic acid, or a portion thereof (e.g., the protospacer of a guide RNA). In other words, the guide nucleic-acid “programs” the napDNAbp (e.g., Cas9, or a variant thereof) to localize and bind to a complementary sequence.

[0055] Without being bound by theory, the binding mechanism of a napDNAbp-guide RNA complex, in general, includes the step of forming an R-loop whereby the napDNAbp induces the unwinding of a double- strand DNA target, thereby separating the strands in the region bound by the napDNAbp. The guide RNA protospacer then hybridizes to the “target strand.” This displaces a “non-target strand” that is complementary to the target strand, which forms the single strand region of the R-loop. In some embodiments, the napDNAbp includes one or 16 / 155B1195.70213WO00#15140132v3more nuclease activities, which then cut the DNA, leaving various types of lesions. For example, the napDNAbp may comprise a nuclease activity that cuts the non-target strand at a first location, and / or cuts the target strand at a second location. Depending on the nuclease activity, the target DNA can be cut to form a “double- stranded break” whereby both strands are cut. In other embodiments, the target DNA can be cut at only a single site, i.e., the DNA is “nicked” on one strand.Naturally-occurring

[0056] The term “naturally-occurring” or “unmodified” or “wild type” as used herein as applied to a nucleic acid, a polypeptide, a cell, or an organism that is found in nature.Nickase

[0057] As used herein, a “nickase” refers to a napDNAbp (e.g., a Cas9 protein) that is capable of cleaving only one of the two complementary strands of a double- stranded target DNA sequence, thereby generating a nick in that strand. In some embodiments, the nickase cleaves a non-target strand of a double stranded target DNA sequence. In some embodiments, the nickase comprises an amino acid sequence with one or more mutations in a catalytic domain of a canonical napDNAbp (e.g., a Cas9 protein), wherein the one or more mutations reduces or abolishes nuclease activity of the catalytic domain. In some embodiments, the nickase is a Cas9 that comprises one or more mutations in a RuvC-like domain relative to a wild type Cas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises one or more mutations in an HNH-like domain relative to a wild type Cas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises an aspartate-to-alanine substitution (D10A) in the RuvCl catalytic domain of Cas9 relative to a canonical SpCas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises an H840A, N854A, and / or N863A mutation relative to a canonical SpCas9 sequence, or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the mutation D15A is used to convert S. auricularis Cas9 to a nickase. In some embodiments, the term “Cas9 nickase” refers to a Cas9 with one of the two nuclease domains inactivated. This enzyme is capable of cleaving only one strand of a target DNA. In some embodiments, the nickase is a Cas protein that is not a Cas9 nickase.

[0058] In some embodiments, the napDNAbp of a base editor is a Cas9 nickase (nCas9) that nicks only a single strand. In other embodiments, the napDNAbp can be selected from the 17 / 155B1195.70213WO00#15140132v3group consisting of: Cas9, Casl2e, Casl2d, Casl2a, Casl2bl, Casl2b2, Casl3a, Casl2c, Casl2d, Casl2e, Casl2h, Casl2i, Casl2g, Casl2f (Casl4), Casl2fl, Casl2j (Cas ), and Argonaute and optionally has a nickase activity such that only one strand is cut. In some embodiments, the napDNAbp is selected from Cas9, Casl2e, Casl2d, Casl2a, Casl2bl, Casl2b2, Casl3a, Casl2c, Casl2d, Casl2e, Casl2h, Casl2i, Casl2g, Casl2f (Casl4), Casl2fl, Casl2j (Cas ), and Argonaute and optionally has a nickase activity such that one DNA strand is cut preferentially to the other DNA strand.Nuclear localization sequence (NLS)

[0059] The term “nuclear localization sequence” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus, for example, by nuclear transport. Nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank et al., international PCT application, PCT / EP2000 / 011690, filed November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for its disclosure of exemplary nuclear localization sequences. In some embodiments, a base editor comprises one or more NLS as described herein.Nucleic acid molecule

[0060] The term “nucleic acid,” as used herein, (also referred to as a “polynucleotide”) refers to a polymer of nucleotides. The polymer may include natural nucleosides (z.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 propynyl uridine, C5 propynyl cytidine, C5 methylcytidine, 7 deazaadenosine, 7 deazaguanosine, 8 oxoadenosine, 8 oxoguanosine, 0(6) methylguanine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, dihydrouridine, methylpseudouridine, 1-methyl adenosine, 1-methyl guanosine, N6-methyl adenosine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2 ’-fluororibose, ribose, 2 '-deoxyribose, 2'-O-methylcytidine, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5' N phosphoramidite linkages).18 / 155B1195.70213WO00#15140132v3pegRNA

[0061] As used herein, the terms “prime editing guide RNA,” “PEgRNA,” “pegRNA,” or “extended guide RNA” refer to a specialized form of a guide RNA that has been modified to include one or more additional sequences for implementing the prime editing as described herein. As described herein, the prime editing guide RNAs comprise one or more “extended regions,” also referred to herein as “extension arms,” of nucleic acid sequence. The extended regions may comprise, but are not limited to, single- stranded RNA or DNA. Further, the extended regions may occur at the 3' end of a traditional guide RNA. In other arrangements, the extended regions may occur at the 5' end of a traditional guide RNA. In still other arrangements, the extended region may occur at an intramolecular region of the traditional guide RNA, for example, in the gRNA core region which associates and / or binds to the napDNAbp. The extended region comprises a “DNA synthesis template” or “reverse transcriptase template” that encodes (by the polymerase / reverse transcriptase of the prime editor) a single- stranded DNA which, in turn, has been designed to be (a) homologous with the endogenous target DNA to be edited, and (b) which comprises at least one desired nucleotide change (e.g., a transition, a transversion, a deletion, or an insertion) to be introduced or integrated into the endogenous target DNA. The extended region may also comprise other functional sequence elements, such as, but not limited to, a “primer binding site” and a “linker” sequence, or other structural elements, such as, but not limited to, aptamers, stem loops, hairpins, toe-loops (e.g., a 3' toeloop), or an RNA-protein recruitment domain (e.g., MS2 hairpin). As used herein, the “primer binding site” comprises a sequence that hybridizes to a single- strand DNA sequence having a 3' end generated from the nicked DNA of the R-loop.

[0062] In certain embodiments, the pegRNAs have a 3' extension arm, a spacer, and a gRNA core. The 3' extension arm further comprises in the 5' to 3' direction a DNA synthesis template, a primer binding site, and a linker. The DNA synthesis template may also be referred to more broadly as the “DNA synthesis template” where the polymerase of a prime editor described herein is not an RT, but another type of polymerase.

[0063] In certain other embodiments, the pegRNAs have a 5' extension arm, a spacer, and a gRNA core. The 5' extension arm further comprises in the 5' to 3' direction a DNA synthesis template, a primer binding site, and a linker. The DNA synthesis template may also be referred to more broadly as the “DNA synthesis template” where the polymerase of a prime editor described herein is not an RT, but another type of polymerase.19 / 155B1195.70213WO00#15140132v3

[0064] In still other embodiments, the pegRNAs have in the 5' to 3' direction a spacer, a gRNA core, and an extension arm. The extension arm is at the 3' end of the pegRNA. The extension arm further comprises in the 5' to 3' direction a homology arm, an edit template, and a primer binding site. The extension arm may also comprise an optional modifier region at the 3' and 5' ends, which may be the same sequences or different sequences. In addition, the 3' end of the pegRNA may comprise a transcriptional terminator sequence. These sequence elements of the pegRNAs are further described and defined herein.

[0065] In still other embodiments, the pegRNAs have, in the 5' to 3' direction, an extension arm, a spacer, and a gRNA core. The extension arm is at the 5' end of the pegRNA. The extension arm further comprises in the 3' to 5' direction a primer binding site, an edit template, and a homology arm. The extension arm may also comprise an optional modifier region at the 3' and 5' ends, which may be the same sequences or different sequences. The pegRNAs may also comprise a transcriptional terminator sequence at the 3' end. These sequence elements of the pegRNAs are further described and defined herein.

[0066] In some embodiments, the spacer sequence of the pegRNA is about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 nucleotides in length. In certain embodiments, the spacer sequence of the pegRNA is about 20 nucleotides in length. In some embodiments, the primer binding site is about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, or about 17 nucleotides in length. In certain embodiments, the primer binding site is about 9, about 10, about 11, about 12, about 13, about 14, or about 15 nucleotides in length. In some embodiments, the homology arm of the pegRNA is about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 nucleotides in length. In some embodiments, the DNA synthesis template is from about 14 to about 21 nucleotides in length.

[0067] In some embodiments, a pegRNA is an “engineered pegRNA” (“epegRNA”).Relative to a pegRNA, an epegRNA comprises an additional structured motif, for example, attached to its 3' end. Such additional structured motifs may stabilize the pegRNA or otherwise prevent it from being degraded. Suitable structured motifs include, but are not limited to, toe-loops, hairpins, stem-loops, pseudoknots, aptamers, G-quadruplexes, tRNAs, riboswitches, and ribozymes.

[0068] pegRNAs are further described, e.g., in International Patent Application No.PCT / US2020 / 023721, filed March 19, 2020, which published as WO 2020 / 191239;20 / 155B1195.70213WO00#15140132v3International Patent Application No. PCT / US2021 / 031439, filed May 7, 2021, which published as WO 2021 / 226558; International Patent Application No. PCT / 2021 / 052097, filed September 24, 2021, which published as WO 2022 / 067130; International Patent Application No. PCT / US2022 / 012054, filed January 11, 2022, which published as WO 2022 / 150790; International Patent Application No. PCT / US2022 / 078655, filed October 25, 2022, which published as WO 2023 / 076898; and International Patent Application No.PCT / US2022 / 074628, filed August 5, 2022, which published as WO 2023 / 015309; the contents of each of which is incorporated by reference herein.

[0069] In the pegRNAs described herein, and any other RNA sequences provided herein, T’ s and U’s may be used interchangeably in the sequences. A person of ordinary skill in the art will understand that T’s in any provided pegRNA or other RNA sequence should be construed as U’s.PE2

[0070] As used herein, “PE2” refers to a PE complex comprising a fusion protein comprising Cas9(H840A) and a variant MMLV RT having the following structure: [NLS]-[Cas9(H840A)]-[linker]-[MMLV_RT(D200N)(T330P)(L603W)(T306K)(W313F)] + a desired pegRNA, wherein the PE fusion has the amino acid sequence of (any of the size-minimized Cas9 proteins described herein may be substituted for the Cas9 protein in this prime editor sequence):MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGN TDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAK VDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPIN ASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFD LAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI TKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGG ASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHA ILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPW NFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYV TEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVE DRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELV21 / 155B1195.70213WO00#15140132v3KVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGL SELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLV SDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYD VRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIV WDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDW DPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDF LEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNF LYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKV LSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDAT LIHQSITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSS L NIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQY PMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVED IHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLT WTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALL QTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWEPEARKETVMGQPTPKTPRQLREF LGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTK PFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAG KLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPWALNPATLL PLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTET EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTS EGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDT S LZJE SPSGGSKRTADGSEFEPKKKRKV (SEQ ID NO: 1)Key:NUCLEAR LOCALIZATION SEQUENCE (NLS)CAS9(H840A)33-AMINO ACID LINKERM-MLV reverse transcriptasePE3

[0071] As used herein, “PE3” refers to a prime editing composition comprising a PE2 prime editor and further comprising a second-strand nicking guide RNA that complexes with PE222 / 155B1195.70213WO00#15140132v3and introduces a nick in the non-edit DNA strand in order to induce preferential replacement of the edit strand.PE3b

[0072] As used herein, “PE3b” refers to a prime editing composition comprising PE2 and further comprising a second- strand nicking guide RNA that complexes with PE2 and introduces a nick in the non-edit DNA strand, wherein the second-strand nicking guide RNA is designed for temporal control such that the second strand nick is not introduced until after the installation of the desired edit. This is achieved by designing the second strand nicking guide RNA with a spacer sequence that comprises complementarity to, and only hybridizes with, the edited strand after installation of the desired nucleotide edit(s), but not the endogenous target DNA sequence. Using this strategy, mismatches between the nicking guide RNA spacer and the unedited target DNA should disfavor nicking by the sgRNA until after the editing event on the PAM strand takes place.PE4

[0073] As used herein, “PE4” refers to a prime editing composition comprising a PE2 and further comprising an MLH1 dominant negative protein variant (z.e., wild- type MLH1 with amino acids 754-756 truncated, which may be referred to herein as “MLH1 A754-756” or “MLHldn”). The MLH1 dominant negative protein variant may be expressed in trans in some embodiments. In some embodiments, a PE4 system comprises a fusion protein comprising a PE2 protein and an MLH1 dominant negative protein joined via an optional linker.PE5 and PE5b

[0074] As used herein, “PE5” refers to a prime editing composition comprising a PE3 prime editor and further comprising an MLH1 dominant negative protein variant (z.e., wild- type MLH1 with amino acids 754-756 truncated, which may be referred to as “MLH1 A754-756” or “MLHldn”). The MLH1 dominant negative variant may be expressed in trans in some embodiments. In some embodiments, a PE5 system comprises a fusion protein comprising a PE2 protein and an MLH1 dominant negative protein joined via an optional linker. “PE5b” refers to a prime editing composition comprising a PE3 and an MLH1 dominant negative protein, wherein the second- strand nicking guide RNA is designed for temporal control such that the second strand nick is not introduced until after the installation of the desired edit. This is achieved by designing the second strand nicking guide RNA with a spacer sequence23 / 155B1195.70213WO00#15140132v3that comprise complementarity to, and hybridize with, only the edited strand after installation of the desired nucleotide edit(s), but not the endogenous target DNA sequence.PE6

[0075] The term “PE6” refers to a suite of prime editors (PE6a, PE6b, PE6c, PE6d, PE6e, PE6f, and PE6g) comprising improved reverse transcriptase and / or Cas9 variants. The improved reverse transcriptase and Cas9 domains of the PE6 variants can also be combined with each other to offer cumulative benefits. For example, a PE6 prime editor comprising an improved reverse transcriptase variant of PE6a and an improved Cas9 variant of PE6e is referred to herein as the prime editor “PE6a-e” (or “PE6e-a”). Any possible combination of PE6 prime editors is contemplated by the present disclosure including, for example, PE6a-e, PE6a-f, PE6a-g, PE6b-e, PE6b-f, PE6b-g, PE6c-e, PE6c-f, PE6c-g, PE6d-e, PE6d-f, and PE6d-g.

[0076] Any of the PE6 prime editors may also comprise the architecture of the PEmax protein as provided herein. In some embodiments, any of the PE6 prime editors provided herein may further comprise additional amino acid mutations, e.g., any of those included in PEmax as provided herein. Any of the size-minimized Cas9 proteins described herein may also be substituted for the Cas9 protein in any of these PE6 prime editor sequences or any other prime editor sequence provided herein.

[0077] In some embodiments, a PE6 protein comprises a reverse transcriptase of the following amino acid sequence (the RT domain of “PE6a”), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:GRPYVTLNLNGMFMDKFKPYSKSNAPITTLEKLSKALSISVEELKAIAELSLDEKYTL KKIPKIDGSKRIVYSLHPKMRLLQSRINERIFKELVVFPSFLFGSVPSKNDVLNSNVKR DYVSCAKAHCGAKTVLKVDISNFFDNIHRDLVRSVFEEILHIKDEALDYLVDICTKDD FVVQGALTSSYIATLCLFAVEGDVVRRAQRKGLVYTRLVDDITVSSKISNYDFSQMQ SHIERMLSEHNLPINKHKTKIFHCSSEPIKVHGLIVDYDSPRLPSDKVKRIRASIHNLKL LAAKNNTKTSVAYRKEFNRCMGRVNELGRVGHEKYESFKKQLQAIKPMPSNRDVA VIDAAIKSLELSYSKGNQNKHWYKRKYDLTRYKMIILTRSESFKEKLECFKSRLASLK PL (SEQ ID NO: 2)

[0078] In some embodiments, a PE6 protein comprises a reverse transcriptase of the following amino acid sequence (the RT domain of “PE6b”), or an amino acid sequence at24 / 155B1195.70213WO00#15140132v3least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:ISSSKHTLSQMNKVSNIVKEPELPDIYKEFKDITADTNTEKLPKPIKGLEFEVELTQEN YRLPIRNYPLTPVKMQAMNDEINQGLKGGIIRESKAINACPVIFVPRKEGTLRMVVDY RPLNKYVKPNVYPLPLIEQLLAKIQGSTIFTKLDLKSAYHQIRVRKGDEHKLAFRCPR GVFEYLVMPYGISTAPAHFQYFINTILGEAKESHVVCYMDDILIHSKSESEHVKHVKD VLQKLKNANLIINQAKCEFHQSQVKFIGYHISEKGLTPCQENIDKVLQWKQPKNRKE LRQFLGSVNYLRKFIPKTSQLTHPLNKLLKKDVRWKWTPTQTQAIENIKQCLVSPPVL RHFDFSKKILLETDVSDVAVGAVLSQKHDDDKYYPVGYYSAKMSKAQLNYSVSDK EMLAIIKSLEHWRHYLESTIEPFKILTDHRNLIGRITNESEPENKRLARWQLFLQDFNF EINYRPGSANHIADALSRIVDETEPIPKDNEDNSINFVNQISI (SEQ ID NO: 3)

[0079] In some embodiments, a PE6 protein comprises a reverse transcriptase of the following amino acid sequence (the RT domain of “PE6c”), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:ISSSKHTLSQMNKVSNIVKEPELPDIYKEFKDITADTNTEKLPKPIKGLEFEVELTQEN YRLPIRNYPLTPVKMQAMNDEINQGLKGGIIRESKAINACPVIFVPRKEGTLRMVVDY RPLNKYVKPNVYPLPLIEQLLAKIQGSTIFTKLDLKSAYHQIRVRKGDEHKLAFRCPR GVFEYLVMPYGIKTAPAHFQYFINTILGEAKESHVVCYMDDILIHSKSESEHVKHVKD VLQKLKNANLIINQAKCEFHQSQVKFLGYHISEKGLTPCQENIDKVLQWKQPKNQKE LRQFLGQVNYLRKFIPKTSQLTHPLNKLLKKDVRWKWTPTQTQAIENIKQCLVSPPV LRHFDFSKKILLETDVSDVAVGAVLSQKHDDDKYYPVGYYSAKMSKAQLNYSVSD KEMLAIIKSLEHWRHYLESTIEPFKILTDHRNLIGRITNESEPENKRLARWQLFLQDFN FEINYRPGSANHIADALSRIVDETEPIPKDNEDNSINFVNQISI (SEQ ID NO: 4)

[0080] In some embodiments, a PE6 protein comprises a reverse transcriptase comprising the following amino acid sequence (the RT domain of “PE6d”), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTP VSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLR EVNKRVEDIHPNVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWR DPEMGISGQLTWTRLPQGFKNSPTLFCEALHRDLADFRIQHPDLILLQYYDDLLLAAT SELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKE TVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKA25 / 155B1195.70213WO00#15140132v3YQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKL DPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSN ARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLD (SEQ ID NO: 5)

[0081] In some embodiments, a PE6 protein comprises a Cas9 protein of the following amino acid sequence (the Cas9 domain of “PE6e”), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE TAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHE RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYA DLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA WMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRN FMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQRNSRERMKRIEEGIKELGSQILKEHPVENTQL QNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDK NRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIA RQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKV REINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGK ATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVV AKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFE LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 6)

[0082] In some embodiments, a PE6 protein comprises a Cas9 protein of the following amino acid sequence (the Cas9 domain of “PE6f”), or an amino acid sequence at least 80%, at least26 / 155B1195.70213WO00#15140132v385%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE TAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFRRLEESFLVEEDKKHE RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYA DLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA WMTRKSEKTITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMVEER LKTYAHLFDNKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLYEHIANLAGSPAIKKGILQTVKVVDELV KVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQ LQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSD KNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFI ARQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYK VREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLV VAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLF ELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLG APAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 7)

[0083] In some embodiments, a PE6 protein comprises a Cas9 protein of the following amino acid sequence (the Cas9 domain of “PE6g”), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGE TAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFRRLEESFLVEEDKKHE RHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEG27 / 155B1195.70213WO00#15140132v3DLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYA DLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFA WMTRKSEKTITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD SVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMVEER LKTYAHLFDNKVMKQLKRCRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLYEHIANLAGSPAIKKGILQTVKVVDELV KVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQ LQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSD KNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFI KRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYK VREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLV VAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLF ELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLG APAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 8)PE7

[0084] The term “PE7” refers to the PE6 prime editors plus a second strand nicking guide RNA. For example, “PE7a” refers to the PE6a prime editor as provided herein, plus a second strand nicking guide RNA.PEmax

[0085] As used herein, “PEmax” refers to a prime editing composition comprising 1) a fusion protein comprising a Cas9 protein variant Cas9(R221K N39K H840A) and a variant MMLV RT having the following structure: [bipartite NLS]-[Cas9(R221K)(N394K)(H840A)]-[linker]-[MMLV_RT(D200N)(T330P)(L603W)]-[bipartite NLS]-[NLS] and 2) a desired PEgRNA, wherein the fusion protein (referred to as the PEmax protein) has the following28 / 155B1195.70213WO00#15140132v3amino acid sequence (any of the size-minimized Cas9 proteins described herein may be substituted for the Cas9 protein in this prime editor sequence):MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLG NTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMA KVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDST DKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI NASGVDAKAILSARLSKSRKLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNF DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYID GGASQEEFYKFIKPILEKMDGTEELLVKLKREDLLRKQRTFDNGSIPHQIHLGE LHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETI TPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKV KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIS GVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFA NRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKV VDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQIL KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKD DSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTK AERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVI TLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVY GDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIET NGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKL IARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSS FEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELA LPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVIL ADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSITGLYETRIDLSOLGGDSGGSSGGSKRTADGSEFESPKKKR KVSGGSSGGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPOAWAETGGMGLAVRQA PLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGT NDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPT SQPEFAFEWRDPEMGISGQETWTREPQGFKNSPTEFNEAEHRDEADFRIQHPDEIEEQ YVDDEEEAATSEEDCQQGTRAEEQTEGNEGYRASAKKAQICQKQVKYEGYEEKEG QRWETEARKETVMGQPTPKTPRQEREFEGKAGFCREFIPGFAEMAAPEYPETKPGTE29 / 155B1195.70213WO00#15140132v3FNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWR RPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALV KQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILA EAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGT SAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKN KDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLlENSSP. S'GG. S'KRTADGSEFESPKKKRKVG. S'GP / M W / . D (SEQ ID NO: 9)Key:BIPARTITE SV40 NUCLEAR LOCALIZATION SEQUENCE (NLS).CAS9(R221K N39K H840A)SGGSx2-BIPARTITE SV40NLS-SGGSx2 LINKERM-MLV reverse transcriptase(D200N T306K W313F T330P L603W)Other linker sequenceBIPARTITE SV40NLSOther linker sequencec-Myc NLSPrime editing

[0086] As used herein, the term “prime editing” refers to an approach for gene editing using napDNAbps, a polymerase (e.g., a reverse transcriptase), and specialized guide RNAs that include a primer binding site and a DNA synthesis template for encoding desired new genetic information (or deleting genetic information) that is then incorporated into a target DNA sequence. Prime editing is described in Anzalone, A. V. et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149-157 (2019), which is incorporated herein by reference. See also International PCT Application, PCT / US2020 / 023721, filed March 19, 2020, and published as WO 2020 / 191239, which is incorporated herein by reference.

[0087] Prime editing represents a platform for genome editing that is a versatile and precise method to directly write new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein (“napDNAbp”) working in association with a polymerase (z.e., in the form of a fusion protein or otherwise provided in trans with the napDNAbp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA (“pegRNA”) that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or 30 / 155B1195.70213WO00#15140132v3RNA) engineered onto a guide RNA (e.g., at the 5' or 3' end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit e.g., a single nucleobase substitution) shares the same sequence as the endogenous strand (or is homologous to it) immediately downstream of the nick site of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and / or replication machinery, the endogenous strand downstream of the nick site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a “search-and-replace” genome editing technology since the prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit that is installed in place of the corresponding target site endogenous DNA strand. The prime editors of the present disclosure relate, in part, to the discovery that the mechanism of target-primed reverse transcription (TPRT) or “prime editing” can be leveraged or adapted for conducting precision CRISPR / Cas-based genome editing with high efficiency and genetic flexibility. TPRT is naturally used by mobile DNA elements, such as mammalian non-LTR retrotransposons and bacterial Group II introns. Cas protein-reverse transcriptase fusions or related systems are used to target a specific DNA sequence with a guide RNA, generate a single strand nick at the target site, and use the nicked DNA as a primer for reverse transcription of an engineered DNA synthesis template that is integrated with the guide RNA. However, while the concept begins with prime editors that use reverse transcriptase as the DNA polymerase component, the prime editors described herein are not limited to reverse transcriptases but may include the use of virtually any DNA polymerase. Indeed, while the application throughout may refer to prime editors with “reverse transcriptases,” it is set forth here that reverse transcriptases are only one type of DNA polymerase that may work with prime editing. Thus, wherever the specification mentions a “reverse transcriptase,” the person having ordinary skill in the art should appreciate that any suitable DNA polymerase may be used in place of the reverse transcriptase. Thus, in one aspect, the prime editors may comprise Cas9 (or an equivalent napDNAbp), which is programmed to target a DNA sequence by associating it with a specialized guide RNA (i.e., pegRNA) containing a spacer sequence that anneals to a complementary sequence (the complementary sequence to an endogenous protospacer sequence) in the target DNA. The pegRNA also contains new genetic information in the form of an extension that encodes a replacement strand of DNA containing a desired nucleotide change which is used to replace a corresponding endogenous DNA strand at the target site. To transfer information from the pegRNA to the target DNA, the mechanism of prime editing 31 / 155B1195.70213WO00#15140132v3involves nicking the target site in one strand of the DNA to expose a 3 '-hydroxyl group. The exposed 3 '-hydroxyl group can then be used to prime the DNA polymerization of the editencoding extension on pegRNA directly into the target site. In various embodiments, the extension — which provides the template for polymerization of the replacement strand containing the edit — can be formed from RNA or DNA. In the case of an RNA extension, the polymerase of the prime editor can be an RNA-dependent DNA polymerase (such as a reverse transcriptase). In the case of a DNA extension, the polymerase of the prime editor may be a DNA-dependent DNA polymerase. The newly synthesized strand (z.e., the replacement DNA strand containing the desired nucleotide edit) that is formed by the prime editor would be homologous to the genomic target sequence (z.e., have the same sequence as), except for the inclusion of one or more desired nucleotide changes (e.g., a single nucleotide substitution, a deletion, or an insertion, or a combination thereof). The newly synthesized (or replacement) strand of DNA may also be referred to as a single strand DNA flap, which would compete for hybridization with the complementary homologous endogenous DNA strand, thereby displacing the corresponding endogenous strand.Resolution of the hybridized intermediate (also referred to as a heteroduplex, comprising the single strand DNA flap synthesized by the reverse transcriptase hybridized to the endogenous DNA strand with the exception of mismatches at positions where desired nucleotide edits are installed in the edit strand) can include removal of the resulting displaced flap of endogenous DNA (e.g., with a 5' end DNA flap endonuclease, FEN1), ligation of the synthesized single strand DNA flap to the target DNA, and assimilation of the desired nucleotide changes as a result of cellular DNA repair and / or replication processes.

[0088] In various embodiments, prime editing operates by contacting a target DNA molecule (for which a change in the nucleotide sequence is desired to be introduced) with a nucleic acid programmable DNA binding protein (napDNAbp) complexed with a prime editing guide RNA (pegRNA). In various embodiments, the prime editing guide RNA (pegRNA) comprises an extension at the 3' or 5' end of the guide RNA, or at an intramolecular location in the guide RNA, and encodes the desired nucleotide change (e.g., single nucleotide substitution, insertion, or deletion). First, the napDNAbp / extended gRNA complex contacts the DNA molecule, and the extended gRNA guides the napDNAbp to bind to a target locus. Next, a nick in one of the strands of DNA of the target locus is introduced (e.g., by a nuclease or chemical agent), thereby creating an available 3' end in one of the strands of the target locus. In certain embodiments, the nick is created in the strand of DNA that corresponds to the R-loop strand, i.e., the strand that is not hybridized to the guide RNA sequence, i.e., the 32 / 155B1195.70213WO00#15140132v3“non-target strand.” The nick, however, could be introduced in either of the strands. That is, the nick could be introduced into the R-loop “target strand” (z.e., the strand hybridized to the protospacer of the extended gRNA) or the “non-target strand” (z.e., the strand forming the single- stranded portion of the R-loop and which is complementary to the target strand). In the next step, the 3' end of the DNA strand (formed by the nick) interacts with the extended portion of the guide RNA in order to prime reverse transcription (z.e., “target- primed RT”). In certain embodiments, the 3' end DNA strand hybridizes to a specific RT priming sequence on the extended portion of the guide RNA, i.e., the “reverse transcriptase priming sequence” or “primer binding site” on the pegRNA. In the next step, a reverse transcriptase (or other suitable DNA polymerase) is introduced that synthesizes a single strand of DNA from the 3' end of the primed site towards the 5' end of the prime editing guide RNA. The DNA polymerase (e.g., reverse transcriptase) can be fused to the napDNAbp or alternatively can be provided in trans to the napDNAbp. This forms a single-strand DNA flap comprising the desired nucleotide change (e.g., the single base change, insertion, or deletion, or a combination thereof) and that is otherwise homologous to the endogenous DNA at or adjacent to the nick site. In the next step, the napDNAbp and guide RNA are released. The final two steps relate to the resolution of the single strand DNA flap such that the desired nucleotide change becomes incorporated into the target locus. This process can be driven towards the desired product formation by removing the corresponding 5' endogenous DNA flap that forms once the 3' single strand DNA flap invades and hybridizes to the endogenous DNA sequence. Without being bound by theory, the cell’s endogenous DNA repair and replication processes resolve the mismatched DNA to incorporate the nucleotide change(s) to form the desired altered product. The process can also be driven towards product formation with “second strand nicking.” This process may introduce at least one or more of the following genetic changes: transversions, transitions, deletions, and insertions.Prime editor

[0089] The term “prime editor” refers to the polypeptide or polypeptide components involved in prime editing as described herein. In some embodiments, a prime editor comprises a fusion construct comprising a napDNAbp (e.g., Cas9 nickase, and / or any of the Cas9 variants provided herein) and a reverse transcriptase (e.g., any of the reverse transcriptase variants provided herein). In some embodiments, a prime editor is capable of carrying out prime editing on a target nucleotide sequence in the presence of a pegRNA (or “extended guide RNA”). In some embodiments, a prime editor comprises a napDNAbp (e.g., Cas9 nickase)33 / 155B1195.70213WO00#15140132v3and a reverse transcriptase provided in trans, i.e., the napDNAbp and the reverse transcriptase are not fused. The in trans napDNAbp and the reverse transcriptase may be tethered via a non-peptide linkage, e.g., an MS2 RNA-protein binding RNA sequence and a MS2 coat protein fused to either the napDNAbp or the reverse transcriptase, or may be unlinked to each other and simply recruited by the pegRNA. In some embodiments, a prime editor composition, system, or complex provided herein comprises a fusion protein or a fusion protein complexed with a pegRNA, and / or further complexed with a second-strand nicking sgRNA. In some embodiments, the prime editor system may also refer to the complex comprising a fusion protein (reverse transcriptase fused to a napDNAbp), a pegRNA, and a regular guide RNA capable of directing the second-site nicking step of the non-edited strand as described herein. In some embodiments, a prime editor comprises any of the size-minimized Cas9 proteins described herein.Primer binding site (PBS)

[0090] The term “primer binding site” or “the PBS” refers to the nucleotide sequence located on a pegRNA as component of the extension arm (typically at the 3' end of the extension arm) and serves to bind to the primer sequence that is formed after Cas9 nicking of the target sequence by the prime editor. As detailed elsewhere, when the Cas9 nickase component of a prime editor nicks one strand of the target DNA sequence, a 3 '-ended ssDNA flap is formed, which serves a primer sequence that anneals to the primer binding site on the pegRNA to prime reverse transcription.Protein, peptide, and polypeptide

[0091] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein, or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a famesyl group, an isofamesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination 34 / 155B1195.70213WO00#15140132v3thereof. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2012)), the contents of which are incorporated herein by reference.Protospacer

[0092] As used herein, the term “protospacer” refers to the sequence (~20 bp) in DNA adjacent to the PAM (protospacer adjacent motif) sequence. The protospacer shares the same sequence as the spacer sequence of the guide RNA. The guide RNA anneals to the complement of the protospacer sequence on the target DNA (specifically, one strand thereof, i.e., the “target strand” versus the “non-target strand” of the target DNA sequence). The skilled person will appreciate that the literature in the state of the art sometimes refers to the “protospacer” as the ~20-nt target- specific guide sequence on the guide RNA itself, rather than referring to it as a “spacer.” Thus, in some cases, the term “protospacer” as used herein may be used interchangeably with the term “spacer.” The context of the description surrounding the appearance of either “protospacer” or “spacer” will help inform the reader as to whether the term is in reference to the gRNA or the DNA target.Spacer sequence

[0093] As used herein, the term “spacer sequence” in connection with a guide RNA refers to the portion of the guide RNA of about 20 nucleotides that contains a nucleotide sequence that shares the same sequence as the protospacer sequence in the target DNA sequence. The spacer sequence anneals to the complement of the protospacer sequence to form a ssRNA / ssDNA hybrid structure at the target site and a corresponding R loop ssDNA structure of the endogenous DNA strand.Subject

[0094] The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian,35 / 155B1195.70213WO00#15140132v3a reptile, a fish, an insect, a fly, or a nematode. In some embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex, and at any stage of development.Target site

[0095] The term “target site” refers to a sequence within a nucleic acid molecule that is modified e.g., edited) by a fusion protein disclosed herein (e.g., a base editor). The target site further refers to the sequence within a nucleic acid molecule to which a complex of, for example, a base editor and a gRNA binds.Treatment

[0096] The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and / or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.Variant

[0097] As used herein, the term “variant” should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature, e.g., a variant Cas9 is a Cas9 comprising one or more changes in amino acid residues (i.e., “substitutions”) as compared to a wild type Cas9 amino acid sequence. The term “variant” encompasses homologous proteins having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with a reference sequence and having the same or substantially the same functional activity or activities as the reference sequence. The term36 / 155B1195.70213WO00#15140132v3also encompasses mutants, truncations, or domains of a reference sequence that display the same or substantially the same functional activity or activities as the reference sequence. Vector

[0098] The term “vector,” as used herein, refers to a nucleic acid that can be modified to encode a gene of interest and that is able to enter a host cell, mutate, and replicate within the host cell, and then transfer a replicated form of the vector into another host cell. Exemplary suitable vectors include viral vectors, such as retroviral vectors or bacteriophages and filamentous phage, and conjugative plasmids. Additional suitable vectors will be apparent to those of skill in the art based on the instant disclosure.DETAILED DESCRIPTION

[0099] The present disclosure provides smaller but effective versions of gene editing systems, including prime editors and base editors, with improved delivery characteristics which are obtained by engineering compact versions of CRISPR Cas9 nucleases, nickases, or nuclease-inactivated proteins (e.g., Streptococcus pyogenes Cas9 (“SpCas9”) and Staphylococcus auricularis Cas9 (“SauriCas9”) nucleases, nickases, or nuclease-inactivated proteins ). The compact versions of the CRISPR Cas9 nucleases, nickases, or nuclease-inactivated proteins (e.g., SpCas9 and SauriCas9 nucleases, nickases, or nuclease-inactivated proteins ) comprise one or more size-decreasing deletions which result in smaller- sized gene editor fusion proteins (e.g., base editor and prime editor fusion proteins) into which they are incorporated. The more compact gene editors provide for improved packaging efficiency and higher expression levels when using an in vivo delivery system, such as an adeno-associated virus vector (AAVs), lipid nanoparticles (LNPs), or engineered virus-like particles (eVLPs). In various aspects, the disclosure provides compositions and methods relating to the compact gene editing systems, including isolated gene editor fusion proteins comprising a reduced-size engineered CRISPR Cas9 protein e.g., SpCas9 or SauriCas9), nucleic acid molecules encoding same, vectors comprising nucleotide sequence encoding same, complexes comprising the compact gene editing systems and one or more guide RNAs, delivery systems (e.g., AAVs) comprising the compact gene editing systems and / or complexes or nucleotide sequences encoding same, cells comprising the compact gene editing systems or complexes described herein, and methods of gene editing using the compact gene editing systems and / or complexes described herein.37 / 155B1195.70213WO00#15140132v3Reduced-Size Cas9 proteins

[0100] In one aspect, the present disclosure provides reduced-sized CRISPR Cas9 proteins. In various embodiments, the reduced-size CRISPR Cas9 protein can be engineered from a naturally occurring CRISPR Cas9 protein. In other embodiments, the reduced-size CRISPR Cas9 protein can be engineered from a non-naturally occurring CRISPR Cas9 protein (e.g., a previously engineered CRISPR Cas9 protein). The CRISPR Cas9 protein may be configured as a nickase in some embodiments. In other embodiments, the CRISPR Cas9 protein may be configured as dead Cas9 or fully nuclease-inactive.

[0101] In various embodiments, the reduced-size CRISPR Cas9 comprises one or more deletions relative to a reference sequence (e.g., a wildtype sequence). In some cases, the reduced-size CRISPR Cas9 may comprise a single deletion of one or more contiguous amino acids. The single deletion of contiguous amino acids (from either end of a Cas9, or from an interior portion of a Cas9) may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418,38 / 155B1195.70213WO00#15140132v3419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 contiguous amino acids.39 / 155B1195.70213WO00#15140132v3

[0102] In other embodiments, the reduced-size CRISPR Cas9 may comprise a combination of at least two deletions, at least three deletions, at least four deletions, at least five deletions, at least six deletions, at least seven deletions, at least eight deletions, at least nine deletions, at least ten deletions, at least eleven deletions, at least twelve deletions, at least thirteen deletions, at least fourteen deletions, at least fifteen deletions, at least sixteen deletions, at least seventeen deletions, at least eighteen deletions, at least nineteen deletions, at least twenty deletions, or more deletions, wherein each deletion is a contiguous range of amino acids comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513,40 / 155B1195.70213WO00#15140132v3514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 contiguous amino acids.

[0103] In still other embodiments, the reduced-size CRISPR Cas9 may comprise a length that is 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588,41 / 155B1195.70213WO00#15140132v3589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167,42 / 155B1195.70213WO00#15140132v31168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430, 1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442, 1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454, 1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 1499, or 1500 contiguous amino acid in length.

[0104] In yet other embodiments, the reduced-size CRISPR Cas9 may comprise one or more deletions that reduce the length of a reference CRISPR Cas9 (e.g., a Streptococcus pyogenes Cas9 (SpCas9) of SEQ ID NO: 10 or a Staphylococcus auricularis Cas9 (“SauriCas9”) of SEQ ID NO: 11) by up to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% of the length of the reference sequence.

[0105] In yet other embodiments, the deletion in the reduced-size CRISPR Cas9 protein may be located anywhere along the length of the reference sequence, such as, but not limited to, at or within amino acids (counting from the N-terminus) 1-50, 25-75, 100-150, 125-175, 150- 43 / 155B1195.70213WO00#15140132v3200, 175-225, 200-250, 225-275, 250-300, 275-325, 300-350, 325-375, 350-400, 375-425, 400-450, 425-475, 450-500, 475-525, 500-550, 525-575, 550-600, 575-625, 600-650, 625-675, 650-700, 675-725, 700-750, 725-775, 750-800, 775-825, 800-850, 825-875, 850-900, 875-925, 900-950, 925-975, 950-1000, 975-1025, 1000-1050, 1025-1075, 1050-1100, 1075-1125, 1100-1150, 1125-1175, 1150-1200, 1175-1225, 1200-1250, 1225-1275, 1250-1300, 1275-1325, 1300-1350, 1325-1375, 1350-1400, 1375-1425, 1400-1450, 1425-1475, or 1450-1500 of the reference sequence (as applicable, depending on the length of the reference sequence (e.g., a Streptococcus pyogenes Cas9 (SpCas9) of SEQ ID NO: 10 or a Staphylococcus auricularis Cas9 (“SauriCas9”) of SEQ ID NO: 11)).

[0106] In addition, the deletion may be introduced into one or more functional domains of a reference CRISPR Cas9, such as a DNA recognition lobe (including the bride helix and wedge domain) such as in the REC2 domain, a nuclease lobe (including a RuvC-like domain and HNH domain), a PAM recognition domain (z.e., the domain which recognizes the Protospacer Adjacent Motif (PAM)), a guide RNA binding domain, and nuclear localization signals. It will be appreciated that functional domains of a Cas9 enzyme include the recognition lobe (e.g., REC2), the nuclease lobe (comprising the RuvC-like and HNH domains), the PAM recognition domain, and the guide RNA binding domain. Together, these domains enable Cas9 to accurately identify in association with a guide RNA and optionally cleave or nick specific DNA sequences.

[0107] In various embodiments, the one or more deletions in the reduced-size CRISPR Cas9 protein may be introduced in a DNA recognition lobe.

[0108] In various embodiments, the one or more deletions in the reduced-size CRISPR Cas9 protein may be introduced in a nuclease lobe, including in a RuvC-like domain and / or an HNH domain.

[0109] In still other embodiments, the one or more deletions in the reduced-size CRISPR Cas9 protein may be introduced in a PAM recognition domain.

[0110] In yet other embodiments, the one or more deletions in the reduced-size CRISPR Cas9 protein may be introduced in a guide RNA binding domain.

[0111] In still other embodiments, the reduced-size CRISPR Cas9 protein may comprise a deletion in a DNA recognition lobe and at least one of a nuclease lobe, a PAM recognition domain, and a guide RNA binding domain.

[0112] In still other embodiments, the reduced-size CRISPR Cas9 protein may comprise a deletion in a nuclease lobe and at least one of a DNA recognition lobe, a PAM recognition domain, and a guide RNA binding domain.44 / 155B1195.70213WO00#15140132v3

[0113] In still other embodiments, the reduced-size CRISPR Cas9 protein may comprise a deletion in a PAM recognition domain and at least one of a nuclease lobe, a DNA recognition lobe, and a guide RNA binding domain.

[0114] In still other embodiments, the reduced-size CRISPR Cas9 protein may comprise a deletion in a guide RNA binding domain and at least one of a nuclease lobe, a DNA recognition lobe, and a PAM recognition domain.

[0115] In various embodiments, the reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, retains the ability to bind to a target nucleic acid, where the guide RNA comprises a nucleotide sequence that is complementary to a nucleotide sequence in the target nucleic acid. In some cases, a reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, exhibits at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or more than 95%, of the binding affinity for a target nucleic acid of a reference Cas9 protein (e.g., Streptococcus pyogenes Cas9 (“SpCas9”) or Staphylococcus auricularis Cas9 (“SauriCas9”)) protein).

[0116] In various embodiments, the reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, retains the ability to bind to a guide RNA. In some cases, a reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, exhibits at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or more than 95%, of the binding affinity for a target nucleic acid of a reference Cas9 protein (e.g., Streptococcus pyogenes Cas9 (“SpCas9”) or Staphylococcus auricularis Cas9 (“SauriCas9”)) protein).

[0117] In various embodiments, the reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, retains a nuclease activity. In some cases, a reduced-size CRISPR Cas9 protein of the present disclosure, when complexed with a guide RNA, exhibits at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or more than 95%, of the nuclease activity of a reference Cas9 protein e.g., Streptococcus pyogenes Cas9 (“SpCas9”) or Staphylococcus auricularis Cas9 (“SauriCas9”)) protein).

[0118] In some embodiments, the reference Cas9 protein is a Streptococcus pyogenes Cas9 (“SpCas9”), which refers to a Cas9 that naturally occurs in Streptococcus pyogenes, and which has the following 1368 (160 kDa) amino acid sequence (SEQ ID NO: 10) (see UniProt Protein Sequence TYL01049.1 and Nucleotide Sequence SJLL01000001).

[0119] MDKKYSIGLDIGTNS VGWAVITDDYKVPSKKLKGLGNTDRHGIKKNLIGALL FDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEED45 / 155B1195.70213WO00#15140132v3KKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLADSTDKVDLRLIYLALAHMIKFRGH FLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASRVDAKAILSARLSKSRRLENLI AQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIG DQYADLFLAAKNLSDATLLSDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVR QQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLAKLNREDL LRKQRTFDNGSIPYQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLAR GNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFK KIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRE MIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDG FANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVV DELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSDILKEYPV ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVL TRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELD KVGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVRVITLKSKLVSDFRKDF QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSE QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVR KVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAY SVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKDPIDFLEAKGYKEVRKDLIIKLP KYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQK QLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFT LTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 10).

[0120] In other embodiments, the reference Cas9 protein is a Staphylococcus auricularis Cas9 (“SauriCas9”), which naturally occurs in Staphylococcus auricularis, and which has the following 1061 (117 kDa) amino acid sequence (SEQ ID NO: 11) (see NCBI Reference Sequence: WP_107392933.1).MQENQQKQNYILGLDIGITSVGYGLIDSKTREVIDAGVRLFPEADSENNSNRRSKRGA RRLKRRRIHRLNRVKDLLADYQMIDLNNVPKSTDPYTIRVKGLREPLTKEEFAIALLH IAKRRGLHNISVSMGDEEQDNELSTKQQLQKNAQQLQDKYVCELQLERLTNINKVR GEKNRFKTEDFVKEVKQLCETQRQYHNIDDQFIQQYIDLVSTRREYFEGPGNGSPYG WDGDLLKWYEKLMGRCTYFPEELRSVKYAYSADLFNALNDLNNLVVTRDDNPKLE YYEKYHIIENVFKQKKNPTLKQIAKEIGVQDYDIRGYRITKSGKPQFTSFKLYHDLKNI FEQAKYLEDVEMLDEIAKILTIYQDEISIKKALDQLPELLTESEKSQIAQLTGYTGTHR46 / 155B1195.70213WO00#15140132v3LSLKCIHIVIDELWESPENQMEIFTRLNLKPKKVEMSEIDSIPTTLVDEFILSPVVKRAFI QSIKVINAVINRFGLPEDIIIELAREKNSKDRRKFINKLQKQNEATRKKIEQLLAKYGN TNAKYMIEKIKLHDMQEGKCLYSLEAIPLEDLLSNPTHYEVDHIIPRSVSFDNSLNNK VLVKQSENSKKGNRTPYQYLSSNESKISYNQFKQHILNLSKAKDRISKKKRDMLLEE RDINKFEVQKEFINRNLVDTRYATRELSNLLKTYFSTHDYAVKVKTINGGFTNHLRK VWDFKKHRNHGYKHHAEDALVIANADFLFKTHKALRRTDKILEQPGLEVNDTTVK VDTEEKYQELFETPKQVKNIKQFRDFKYSHRVDKKPNRQLINDTLYSTREIDGETYV VQTLKDLYAKDNEKVKKLFTERPQKILMYQHDPKTFEKLMTILNQYAEAKNPLAAY YEDKGEYVTKYAKKGNGPAIHKIKYIDKKLGSYLDVSNKYPETQNKLVKLSLKSFRF DIYKCEQGYKMVSIGYLDVLKKDNYYYIPKDKYEAEKQKKKIKESDLFVGSFYYND LIMYEDELFRVIGVNSDINNLVELNMVDITYKDFCEVNNVTGEKRIKKTIGKRVVLIE KYTTDILGNLYKTPLPKKPQLIFKRGEL (SEQ ID NO: 11).

[0121] In some embodiments, the minimized Cas9 is a minimized Streptococcus pyogenes Cas9 (SpCas9) protein that comprises one or more deletions of the following contiguous ranges of amino acid residues: 172-176, 172-182, 173-177, 174-178, 175-179, 176-180, 177-181, 172-182, 174-188, 209-214, 211-216, 213-218, 646-657, 646-649, 647-650, 648-651, 668-675, 670-677, 671-677, 672-679, 673-680, 818-830, and / or 819-831 relative to an SpCas9 protein comprising an amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 10.

[0122] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 172-176 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0123] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 172-182 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0124] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 173-177 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0125] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 174-178 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0126] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 175-179 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0127] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 176-180 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.47 / 155B1195.70213WO00#15140132v3

[0128] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 177-181 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0129] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 172-182 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0130] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 174-188 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0131] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 209-214 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0132] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 211-216 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0133] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 213-218 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0134] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 646-657 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0135] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 646-649 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0136] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 647-650 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0137] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 648-651 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0138] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 668-675 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0139] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 670-677 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0140] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 671-677 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0141] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 672-679 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0142] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 673-680 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0143] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 818-830 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.

[0144] In some embodiments, the minimized SpCas9 protein comprises a deletion of residues 819-831 relative to the reference sequence of SpCas9 of SEQ ID NO: 10.48 / 155B1195.70213WO00#15140132v3

[0145] In other embodiments, the minimized Cas9 is a minimized Staphylococcus auricularis Cas9 (“SauriCas9”) protein that comprises one or more deletions of the following contiguous ranges of amino acid residues: 1-3, 1-6, 125-132, 125-140, 128-135, 322-329, 725-766, 743-750, 1046-1061, or 1051-1061 relative to a SauriCas9 protein comprising an amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 11.

[0146] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 1-3 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0147] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 1-6 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0148] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 125-132 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0149] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 125-140 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0150] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 128-135 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0151] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 322-329 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0152] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 725-766 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0153] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 743-750 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0154] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 1046-1061 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.

[0155] In some embodiments, the minimized SauriCas9 protein comprises a deletion of residues 1051-1061 relative to the reference sequence of SauriCas9 of SEQ ID NO: 11.Adenosine Deaminases

[0156] In various embodiments, the disclosure contemplates size-minimized base editors. In some cases, the base editors can be adenine base editors. The adenine base editors comprise one or more adenosine deaminases. Adenosine deaminases are described, for example, in International PCT Application Publication No. WO 2018 / 027078, published February 8, 2018, which is incorporated herein by reference. In some embodiments, an adenosine 49 / 155B1195.70213WO00#15140132v3deaminase comprises any of the following amino acid sequences, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the following amino acid sequences (Table 1):

[0157] Table 1 - Exemplary adenosine deaminases50 / 155B1195.70213WO00#15140132v351 / 155B1195.70213WO00 #15140132v352 / 155B1195.70213WO00 #15140132v353 / 155B1195.70213WO00 #15140132v354 / 155B1195.70213WO00 #15140132v355 / 155B1195.70213WO00 #15140132v356 / 155B1195.70213WO00 #15140132v3Guide RNAs (gRNAs)

[0158] In general, a gRNA is any RNA sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequencespecific binding of a napDNAbp (e.g., Cas9, which may be part of a base editor) to the target sequence. In some embodiments, the degree of complementarity between the spacer of a gRNA and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more (or the spacer and the corresponding target sequence comprise one, two, three, four, five, six, seven, eight, nine, or ten amino acid differences). In certain embodiments, the spacer of a gRNA is 100% complementary to its corresponding target sequence. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows- Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).57 / 155B1195.70213WO00#15140132v3

[0159] The ability of a gRNA to direct sequence- specific binding of a base editor to a target sequence may also be assessed by any suitable assay. For example, a base editor and gRNA may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the base editor and gRNA or by transfection of a ribonucleoprotein (RNP) complex, followed by an assessment of preferential cleavage, nicking, or editing within the target sequence. Similarly, cleavage or editing of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, base editor, and gRNA to be tested and a control gRNA different from the test gRNA, and comparing binding or rate of cleavage or editing at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will be apparent to those skilled in the art.

[0160] In some embodiments, a gRNA is about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 75, about 100, or more nucleotides in length. In some embodiments, a gRNA is about 50-150, about 60-140, about 70-130, about 80-120, or about 90-110 nucleotides in length. In some embodiments, the spacer sequence of a gRNA is about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 nucleotides in length.

[0161] In some embodiments, a gRNA comprises the structure 5 '-[spacer sequence] -[backbone sequence]-3'. In some embodiments, a gRNA comprises an optional linker sequence. For example, the gRNAs provided herein may comprise an optional linker sequence between the spacer and the backbone sequence of the gRNA. In certain embodiments, the optional linker sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, or at least 50 nucleotides in length.

[0162] In some embodiments, a gRNA is a pegRNA or an epegRNA.Delivery Methods and AAV Particles

[0163] The present disclosure provides, in some aspects, methods comprising delivering any of the size-minimized Cas9 proteins, fusion proteins, gRNAs, complexes, polynucleotides, vectors, and pharmaceutical compositions described herein. In some embodiments, a gRNA 58 / 155B1195.70213WO00#15140132v3is delivered to a cell, e.g., in combination with a size-minimized Cas9 protein, or a fusion protein, base editor or prime editor comprising a size-minimized Cas9 protein. The size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, and / or gRNA, can be delivered in any form, e.g., each may independently be delivered in DNA, RNA, or protein form (for the size-minimized Cas9 protein, fusion protein, base editor, or prime editor). Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in cells (e.g., mammalian cells) or target tissues. Such methods can be used to administer nucleic acids encoding components of a size-minimized Cas9 protein, or fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, and gRNA to cells in culture, or in a host organism. Non-viral vector delivery systems include ribonucleoprotein (RNP) complexes, DNA plasmids, RNA, naked nucleic acid, and nucleic acid complexed with, part of, encapsulated by, or associated with a delivery vehicle, such as a liposome or lipid nanoparticle. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Feigner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10): 1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51 (1 ):31-44 (1995); Haddada et al., in Current Topics in Microbiology and Immunology Doerfler and Bihm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0164] In some embodiments, the gRNA and size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, are delivered or administered as a proteimRNA complex. In certain embodiments, the method of delivery comprises delivering an RNP complex. For example, RNP delivery of base editors markedly increases the DNA specificity of base editing. RNP delivery of base editors leads to fewer off-target effects. RNP delivery ablated off-target editing at non-repetitive sites while maintaining on-target editing comparable to plasmid delivery, and greatly reduced off-target editing even at the highly repetitive VEGFA site 2. See Rees, H. A. et al., Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery, Nat. Commun. 8, 15790 (2017), which is incorporated herein by reference.

[0165] Methods of non-viral delivery of nucleic acids include RNP complexes, lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipidmucleic acid conjugates, naked DNA, artificial virions, and agent- 59 / 155B1195.70213WO00#15140132v3enhanced uptake of DNA. Lipofection is described in, e.g., U. S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355, and lipofection reagents are sold commercially e.g., Lipofectamine, Lipofectamine 2000, Lipofectamine 3000, Transfectam™, and Lipofectin™). In certain embodiments of the disclosed methods of editing, a cationic lipid comprising Lipofectamine 2000 is used for delivery of nucleic acids to cells. Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner (see WO 1991 / 17424 and WO 1991 / 16024). Delivery of, e.g., Cas9 proteins and gRNAs using cationic lipids and cationic polymers is also described in International Patent Application Publication Nos. WO 2015 / 035136 and WO 2016 / 070129, each of which is incorporate herein by reference. Delivery can be to cells (e.g., in vitro or ex vivo administration) or target tissues (e.g., in vivo administration).

[0166] The preparation of lipidmucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); GaoAhmad et al., Cancer Res. 52:4817-4820 (1992); U. S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, 4,946,787, 9,526,784, and 9,737,604).

[0167] The use of RNA or DNA viral based systems for the delivery of nucleic acids (e.g., nucleic acids encoding a size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, and gRNA as described herein) take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo), or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated, and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

[0168] In some embodiments, an adeno-associated virus (AAV)-based system is used for delivery of nucleic acid molecule(s) encoding a gRNA and a size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein.Particularly in applications where transient expression is preferred, adenoviral-based systems 60 / 155B1195.70213WO00#15140132v3may be used. Adenoviral-based vectors are capable of very high transduction efficiency in many different cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. AAV vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U. S. Pat. No. 4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors is described in a number of publications, including U. S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol.5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); Samulski et al., J. Virol. 63:03822-3828 (1989); and International Patent Application No. PCT / US2023 / 066389, filed April 28, 2023.

[0169] Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and q / 2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide(s) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. In some embodiments, the AAV targets the central nervous system (CNS). In some embodiments, the AAV targets neurons. In certain embodiments, the AAV is AAV9.

[0170] In various embodiments, the constructs for expressing a gRNA (including a pegRNA) and size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, described herein may be engineered for delivery in one or more AAV vectors. An AAV as related to any of the methods and compositions provided 61 / 155B1195.70213WO00#15140132v3herein may be of any serotype including any derivative or pseudotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 2 / 1, 2 / 5, 2 / 8, 2 / 9, 3 / 1, 3 / 5, 3 / 8, or 3 / 9). An AAV may comprise a genetic load (z.e., a recombinant nucleic acid vector that expresses gene products of interest, such as a base editor and / or gRNA that is carried by the AAV into a cell) that is to be delivered to a cell.

[0171] In one aspect, the present disclosure provides one or more AAV particles comprising one or more polynucleotides encoding any of the gRNAs and size-minimized Cas9 proteins, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, or portion(s) thereof, provided herein. In some embodiments, the polynucleotide encoding the size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, is split between a first and a second AAV particle. In certain embodiments, the polynucleotides encoding the split size-minimized Cas9 protein, or a fusion protein, base editor, or prime editor comprising a size-minimized Cas9 protein, comprise an N-intein and a C-intein (i.e., the N-terminal portion comprises an N-intein, and the C-terminal portion comprises a C-intein). In some embodiments, the first and / or the second AAV particle further comprises the polynucleotide encoding the gRNA (including a pegRNA).Pharmaceutical Compositions

[0172] Other aspects of the present disclosure relate to pharmaceutical compositions comprising any of the size-minimized Cas9 proteins, fusion proteins, base editors, prime editors, complexes, polynucleotides, vectors, and / or cells described herein. The term “pharmaceutical composition,” as used herein, refers to a composition formulated for pharmaceutical use. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises additional agents (e.g., for specific delivery, increasing half-life, or other therapeutic compounds).

[0173] As used here, the term “pharmaceutically-acceptable carrier” (or “pharmaceutically acceptable excipient”) means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the compound from one site (e.g., the delivery site) of the body, to another site (e.g., organ, tissue or portion of the body). A pharmaceutically acceptable carrier is “acceptable” in the sense of being compatible with the other ingredients 62 / 155B1195.70213WO00#15140132v3of the formulation and not injurious to the tissue of the subject (e.g., physiologically compatible, sterile, physiologic pH, etc.). Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids; (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, and antioxidants can also be present in the formulation. Terms such as “excipient,” “carrier,” “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” or the like are used interchangeably herein.

[0174] In some embodiments, the pharmaceutical composition is formulated for delivery to a subject for gene editing e.g., base editing or prime editing).

[0175] The pharmaceutical compositions described herein may be administered or packaged as a unit dose, for example. The term “unit dose” when used in reference to a pharmaceutical composition of the present disclosure refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

[0176] In some embodiments, an article of manufacture containing materials useful for the treatment of the diseases described above is included. In some embodiments, the article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. In some embodiments, the container holds a composition 63 / 155B1195.70213WO00#15140132v3that is effective for treating a disease and may have a sterile access port. For example, the container may be an intravenous solution bag or a vial having a stopper pierce-able by a hypodermic injection needle. The active agent in the composition is a compound of the invention. In some embodiments, the label on or associated with the container indicates that the composition is used for treating the disease of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer’s solution, or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.Polynucleotides, Vectors, Cells, and Kits

[0177] The present disclosure provides, in some aspects, polynucleotides and vectors encoding any of the size-minimized Cas9 proteins, fusion proteins, base editors, prime editors, and / or complexes described herein. In some embodiments, the polynucleotides and vectors provided herein comprise DNA (e.g., plasmid DNA or viral DNA). In some embodiments, the polynucleotides and vectors provided herein comprise RNA (e.g., mRNA or viral RNA).

[0178] Cells that may contain any of the size-minimized Cas9 proteins, fusion proteins, base editors, prime editors, complexes, polynucleotides, and / or vectors described herein are also provided by the present disclosure. The methods described herein may be used to deliver a guide RNA and fusion protein, base editor, or prime editor comprising a disclosed size-minimized Cas9 protein into a eukaryotic cell (e.g., a mammalian cell, such as a human cell). In some embodiments, the cell is in vitro (e.g., a cultured cell). In some embodiments, the cell is in vivo (e.g., in a subject, such as a human subject). In some embodiments, the cell is ex vivo (e.g., isolated from a subject and may be administered back to the same or a different subject).

[0179] In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of a base editing system as described herein (such as by transient transfection of one or more vectors, or transfection 64 / 155B1195.70213WO00#15140132v3with RNA), and modified through the activity of a fusion protein, base editing, or prime editing complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence.

[0180] The size-minimized Cas9 proteins, fusion proteins, base editors, prime editors, complexes, polynucleotides, and / or vectors described herein may also be assembled into kits. In some embodiments, the kit comprises polynucleotides for expression of the size-minimized Cas9 proteins, fusion proteins, base editors, prime editors, and / or complexes described herein. In some embodiments, the kit comprises appropriate gRNAs or nucleic acid vectors for the expression of gRNAs to target the size-minimized Cas9 protein of a fusion protein, base editor, or prime editor to a desired target sequence.

[0181] The kits described herein may include one or more containers housing components for performing the methods described herein, and optionally instructions for use. Any of the kits described herein may further comprise components needed for performing the methods described herein. Each component of the kits, where applicable, may be provided in liquid form (e.g., in solution) or in solid form, (e.g., a dry powder). In certain cases, some of the components may be reconstitutable or otherwise processible (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water), which may or may not be provided with the kit.

[0182] In some embodiments, the kits may optionally include instructions and / or promotion for use of the components provided. As used herein, “instructions” can define a component of instruction and / or promotion, and typically involve written instructions on or associated with packaging of the disclosure. Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and / or web-based communications, etc. The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which can also reflect approval by the agency of manufacture, use, or sale for animal administration. As used herein, “promoted” includes all methods of doing business including methods of education, hospital and other clinical instruction, scientific inquiry, drug discovery or development, academic research, pharmaceutical industry activity including pharmaceutical sales, and any advertising or other promotional activity including written, oral, and electronic communication of any form, associated with the disclosure. Additionally, the kits may include other components depending on the specific application, as described herein.65 / 155B1195.70213WO00#15140132v3

[0183] The kits may contain any one or more of the components described herein in one or more containers. The components may be prepared sterilely, packaged in a syringe, and shipped refrigerated. Alternatively, they may be housed in a vial or other container for storage. A second container may have other components prepared sterilely. Alternatively, the kits may include the active agents premixed and shipped in a vial, tube, or other container.

[0184] The kits may have a variety of forms, such as a blister pouch, a shrink-wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box, or a bag. The kits may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped. The kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. The kits may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration, etc.EXAMPLESExample 1. Generation of size-minimized Cas9 proteins for prime and base editing

[0185] Current state-of-the-art Cas9-based genome editors, such as prime editors and base editors, are large — the PE6c prime editor protein is about 225 kDa and is encoded in a gene that is -5900 nucleotides long. The large size of prime editors and other Cas9-based genome editing technologies limits opportunities for their efficient delivery in vivo via adeno-associated viruses (AAVs),1,2lipid nanoparticles (LNPs),3engineered virus-like particles (eVLPs),4and other clinically promising delivery modalities (FIGs. 1A-1C). This issue is especially relevant for AAVs, as each AAV genome has a -4900 bp packaging limit above which AAV production efficiency drops substantially.

[0186] For example, the PE6c prime editor cannot be packaged into a dual- AAV genome alongside three Cas9 guide RNAs — which are required for efficient editing of the cystic fibrosis- causing mutation CFTR. F508A5— without compromising on delivery potency by using shorter, weaker promoters to drive prime editor protein expression. The packaging efficiency of cytosine base editors that make use of small naturally occurring Cas9 proteins, such as S. auricularis Cas9 (SauriCas9), into a single AAV genome is also inefficient due to the need to include a uracil glycosylase inhibitor (UGI) domain. The large size of genome editor proteins also prohibits the inclusion of tissue-specific enhancer and promoter elements 66 / 155B1195.70213WO00#15140132v3that only express genes in specific tissues, a feature that can augment the safety of AAV-delivered genes.

[0187] Prime and base editors that use small, engineered S. pyogenes Cas9 (SpCas9) domains would enable applications that currently remain out of reach, including efficient packaging and high expression in dual- and single- AAVs. This project has sought to engineer small variants of SpCas9 and SauriCas9 for use as prime editors and base editors. SpCas9 has an NGG PAM and SauriCas9 has an NNGG PAM. Both enable versatile targeting to the genomes of humans and other organisms. The strategies explored in this project could be applied to other Cas9 orthologs.Generation of small S. pyogenes Cas9 proteins for prime editingSize budget for a dual-AAV prime editor

[0188] It was sought to generate size-minimized SpCas9 proteins that could support efficient dual-AAV prime editing using three guide RNAs and a strong pan-tissue promoter (CBh promoter). This dual-AAV architecture has been described for PEmax with two guide RNAs2 and for PE6c with dual guide RNAs6, but not for three-guide prime editors as has been described for correcting CFTR. F508A.5The size of each element in these previously described dual-AAV architectures is outlined below in the context of an application with three guide RNAs (an epegRNA, a nicking sgRNA, and a catalytically inactive sgRNA) (FIGs. 2A-2B).

[0189] The PE6c protein is encoded by -6120 nucleotides of sequence, including fusion protein linkers and nuclear localization sequences (NLSs). It must be split in two halves (each half in a separate AAV genome) and reconstituted using the NpuN / C split-intein system, which is -410 bp long. The epegRNA is -180 bp long, the nicking sgRNA is -100 bp long, and the catalytically inactive sgRNA is -90 bp long. Each is guide RNA is driven by a U6 promoter (of human, mouse, bovine, or other origin) that is 260-320 bp long. The Cbh promoter driving the expression of each PE6c half is -800 bp long. Terminators for the prime editor protein halves such as the SV40 late polyA sequence are 130 bp long. 3’ and 5’ ITRs for AAV genome production are each 130 bp long. This totals -10,160 bp of sequence, about 360 bp above the 9800 bp packaging limit of a dual AAV system.Analysis of a dataset of truncated SpCas9 variants

[0190] It was reasoned that the size of the SpCas9 protein in a prime editor could be reduced by identifying regions of the protein that are tolerant of deletions. Potential regions were nominated for deletion by analyzing a dataset of SpCas9 deletion variants generated by 67 / 155B1195.70213WO00#15140132v3Shams et al.7This work generated libraries of SpCas9 deletions via iterative size exclusion and recombination and subjected the libraries to a DNA binding assay in E. coli. Cas9 variants that passed the flow cytometry-based selection were enriched relative to preselection frequencies, and deep sequencing identified variants that were enriched (i.e. more functional) post-selection. Of note, the assays used herein assessed DNA binding by Cas9, not cutting of either DNA strand, which is required of Cas9 proteins in prime editing contexts.

[0191] Regions of the Cas9 protein that are tolerant of deletion were identified by plotting the start position of an enriched deletion against the frequency with which deletions starting at that position are enriched. It was hypothesized that higher numbers of enriched variants that begin at a particular position were indicative of that start position being more tolerant of deletion. From this, where the start positions with high frequencies of enriched variants resided on the structure of Cas9 were manually inspected. An initial set of deletion variants to test was defined that deleted unstructured loops and / or solvent-exposed helices beginning near high-frequency start positions. From this initial test, four variants were identified (A175-182, A211-216, A670-677, and A818- 830) that showed little or no loss of activity when used in the context of a prime editor (FIGs. 3A and 3C).Further refinement of deletion regions

[0192] It was next sought to refine the regions identified in the initial test of deletion regions. The deletions A175-182, A211-216, A670-677 and A818-830 retained activity in the context of a prime editor. Therefore, additional SpCas9 variants were generated with deletions in the vicinity of these regions. The objective was to identify the largest single deletion that could be made in these regions while still preserving the activity of SpCas9 as a prime editor. 95 variants were tested for prime editing activity (FIGs. 4A-4H). Some of the deletion variants that were identified in the initial small experiment (such as A211-216) did not show robust editing activity in this larger experiment, possibly because the variants were tested on a different edit (CFTR. 508A correction in the larger experiment in FIGs. 4A-4H versus HEK3 CTT insertion in the smaller experiment in FIG. 3C). Nonetheless, deletion variants that preserved editing activity or led to modest reductions in editing activity: SpCas9 A172-182, A209-214, A646-657, A672-679, and A819-831.Testing combinations of deletions

[0193] All the experiments conducted to this point were on SpCas9 variants with single deletion regions. It was next sought to test if combining the deletion regions identified in the 68 / 155B1195.70213WO00#15140132v3previous experiment could lead to smaller functional prime editors. All possible combinations of the deletions A172-182, A209-214, A646-657, A672-679, and A819-831 were tested for editing activity (FIG. 5). None of the combinations showed robust editing activity.Examining the REC2 domain as a deletion target

[0194] The REC2 domain of SpCas9, spanning residues 175-307, is not essential for Cas9’s activity as a double- stranded DNA nuclease (FIGs. 6A-6B).8It was therefore hypothesized that it could be deleted, either completely or partially, in the context of a prime editor and still maintain editing activity. The REC2 domain nonetheless engages with other domains of the Cas9 protein and with the target DNA and sgRNA via several residues, and one of the mutations present in the engineered prime editor variant PEmax, R221K, is also found in the REC2 domain (these residues are depicted in FIG. 7). Complete and partial deletions of the SpCas9 REC2 domain were tested in the context of a prime editor, as well as alanine substitutions of some of the residues shown in FIG. 7 to determine their essentiality (FIGs. 8A-8B). FIG. 8A shows deletions starting from the REC2 N-terminus (residue 175) and extending towards the C terminus. FIG. 8B shows deletions starting from the REC2 C-terminus (residue 307) and extending towards the N terminus. For each of these deletion variants, both simple deletion of the residues as well as replacement of the deleted residues was tested with a SGGSSGGS (SEQ ID NO: 12) peptide linker. The same control conditions showing standard PE6c and alanine substitutions of important REC2 residues are shown in FIG. 8 A and 8B. It was found that many of the important REC2 residues can be substituted to alanine(s) while still retaining robust editing activity, suggesting that they may not be essential for prime editing. However, all tested deletions of the REC2 domain, either as a simple deletion or as a deletion with engraftment of a SGGSSGGS (SEQ ID NO: 12) peptide linker, showed little to no editing activity.

[0195] There may be the potential to use computational protein design tools, such as RFDiffusion9 for de novo structure generation and ProteinMPNNlO for structure-to- sequence generation, to redesign smaller versions of the REC2 domain (or other regions of the SpCas9 protein) while still retaining the positions of essential residues. Such designs were generated as shown in FIG. 9.Generation of small S. auricularis Cas9 proteins for base editingTesting deletions in S. auricularis Cas9for cytosine base editing

[0196] Another application of size-minimized Cas9 proteins is for use as base editors. In particular, cytosine base editors (CBEs), which require a UGI fused to the Cas9 domain for 69 / 155B1195.70213WO00#15140132v3efficient C-to-T base conversion, package inefficiently in a single AAV genome when used with naturally-occurring small Cas9s (in the range of 1050-1100 residues) such as S. auricularis Cas9 (SauriCas9) and S. aureus Cas9. It was sought to explore whether SauriCas9 could be size minimized while still retaining activity as a CBE. Importantly, base editing does not strictly rely on DNA cutting to perform its action; catalytically dead Cas9’s that have both nuclease domains inactivated can function as base editors as can nickase Cas9’s with the RuvC nuclease domain inactivated. Prime editing, by contrast, necessitates the use of a catalytically competent Cas9 nickase with the HNH nuclease domain inactivated (or, in some compositions of matter, Cas9 nuclease with no domains inactivated). It was hypothesized that, compared to prime editors, the need for base editors to bind, but not necessarily cut, DNA might make the Cas9 component of a base editor more amenable to deletions relative to what we observed for prime editors.

[0197] The dataset that was analyzed to nominate deletion variants for use in prime editors was collected for SpCas9. No similar dataset exists for SauriCas9. To nominate deletion variants of SauriCas9 to test as a CBE, a structural alignment of SauriCas9 to SpCas9 were performed and the deletion regions that were tested for SpCas9 were annotated onto equivalent positions on the SauriCas9 structure. Nomination of deletion regions in this manner — on the basis of structural similarity — could be performed for other Cas9 orthologs as well.

[0198] These SauriCas9 deletion variants were tested as cytosine base editors for stop codon installation in the PRNP gene (FIG. 10). It was found that numerous tested deletion variants supported efficient base editing with little to no reduction in editing efficiency. A similar approach to that piloted for prime editor size reduction, of first refining individual deletion regions and then assessing deletion regions in combination, could be employed on SauriCas9 base editors.References for Example 1

[0199] 1. Davis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., and Liu, D. R. (2022). Efficient in vivo base editing via single adeno-associated viruses with size- optimized genomes encoding compact adenine base editors. Nat Biomed Eng. doi.org / 10.1038 / s41551-022-00911-4.

[0200] 2. Davis, J. R., Banskota, S., Levy, J. M., Newby, G. A., Wang, X., Anzalone, A. V., Nelson, A. T., Chen, P. J., Hennes, A. D., An, M., et al. (2024). Efficient prime editing in70 / 155B1195.70213WO00#15140132v3mouse brain, liver and heart with dual AAVs. Nat Biotechnol 42, 253-264. doi.org / 10.1038 / s41587-023-01758-z.

[0201] 3. Zhao, Y., and Huang, L. (2014). Lipid nanoparticles for gene delivery. Adv Genet 88, 13-36. doi.org / 10.1016 / B978-0-12-800148-6.00002-X.

[0202] 4. Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250-265.el6. doi.org / 10.1016 / j.cell.2021.12.021.

[0203] 5. Sousa, A. A., Hemez, C., Lei, L., Traore, S., Kulhankova, K., Newby, G. A., Doman, J. L., Oye, K., Pandey, S., Karp, P. H., et al. (2024). Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells. Nat Biomed Eng. doi.org / 10.1038 / s41551-024-01233-3.

[0204] 6. Doman, J. L., Pandey, S., Neugebauer, M. E., An, M., Davis, J. R., Randolph, P. B., McElroy, A., Gao, X. D., Raguram, A., Richter, M. F., et al. (2023). Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell 186, 3983-4002.e26. doi.org / 10.1016 / j.cell.2023.07.039.

[0205] 7. Shams, A., Higgins, S. A., Fellmann, C., Laughlin, T. G., Oakes, B. L., Lew, R., Kim, S., Lukarska, M., Arnold, M., Staahl, B. T., et al. (2021). Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modules. Nat Commun 12, 5664. doi.org / 10.1038 / s41467-021-25992-8.

[0206] 8. Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., and Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935-949. doi.org / 10.1016 / j.cell.2014.02.001.

[0207] 9. Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahem, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023). De novo design of protein structure and function with RFdiffusion. Nature 620, 1089-1100. doi.org / 10.1038 / s41586-023-06415-8.

[0208] 10. Dauparas, J., Anishchenko, I., Bennett, N., Bai, H., Ragotte, R. J., Milles, L. F., Wicky, B. I. M., Courbet, A., de Haas, R. J., Bethel, N., et al. (2022). Robust deep learning based protein sequence design using ProteinMPNN. Science 378, 49-56.doi.org / 10.1126 / science. add2187.Example 2. Engineering size-minimized prime editors for improved AAV-mediated in vivo delivery71 / 155B1195.70213WO00#15140132v3Introduction

[0209] Prime editing is a programmable gene editing technology capable of correcting a wide range of genetic diseases, including cystic fibrosis (CF). However, in vivo delivery remains a challenge because the size of the optimized prime editing system exceeds the packaging capacity of adeno-associated virus (AAV) vectors. Therefore, this example investigated whether minimizing the Cas9 domain of the prime editor could create a compact variant that enables in vivo delivery to correct CF and other genetic diseases. Using a structure-guided approach and iterative testing, five small regions within Cas9 were identified and optimized that could be deleted without significantly impacting activity. However, combining deletions led to a significant loss of activity, underscoring the limitations of a deletion-based strategy and motivating alternative or complementary approaches for developing compact prime editors for high-efficiency, AAV-mediated in vivo delivery.

[0210] Genetic diseases like cystic fibrosis (CF) are caused by small mutations in DNA that can significantly impact quality of life and lead to life threatening complications. CF, for instance, is commonly caused by a three-base-pair deletion (F508del) in the CFTR gene, resulting in thick mucus accumulation in the lungs and increased susceptibility to respiratory infections (1).

[0211] With more than 6,000 known genetic disorders in humans, there is a pressing need for versatile gene editing tools and efficient delivery methods (2). One promising approach is prime editing, a CRISPR-based technology capable of introducing precise insertions, deletions, and substitutions in the genome (3).

[0212] Despite prime editing’s therapeutic promise, one major challenge is the efficient delivery of the editor and necessary accessory components to relevant tissues in vivo. Adeno-associated viruses (AAVs) have emerged as a leading delivery method due to their clinical validation, favorable safety profile, and current use in several FDA-approved therapies (4). However, their limited cargo capacity poses a significant constraint, especially for cystic fibrosis where the delivery of an additional dead sgRNA (dsgRNA) is necessary to achieve optimal in vivo editing (5).

[0213] Therefore, one approach to enable high-expression, high-efficiency dual AAV PE systems is to engineer a more compact prime editor. Minimizing the size of the prime editor would enable inclusion of stronger promoters, additional components like dead sgRNAs (dsgRNAs), and enhance expression and editing efficiency. This approach could make prime editing more viable for diseases like CF and broadly expand the applicability of AAV-based gene editing therapies.72 / 155B1195.70213WO00#15140132v3ResultsInitial Deletion Screen Identifies Five Small Regions in Cas9 That Tolerate Deletion In Prime Editors

[0214] Results are shown in FIG. 12A and 12B. Data shows that 22 single- deletion prime editor variants were evaluated for their ability to make the HEK3 +1 CTT insertion in HEK293 T cells. Five deletion variants, namely, A174-182, A211-216, A644-655, A670-677, and A818-830, retained significant editing activity. These deletion regions served as the basis for optimizing single-deletions in prime editors. FIG. 12B shows residue deletions A174-182, A211-216, A644-655, A670-677, and A818-830 relative location within the prime editor. Focused Deletion Screen Identifies Optimal Single-Deletions Across Five Cas9 Regions

[0215] Results are shown in FIG. 13. Ninety-five (95) prime editor variants, each containing a unique deletion spanning subsets of the five regions, were tested to determine the optimal single- deletion variant within each of the five previously identified nonessential Cas9 regions. A174-182, A209-214, A646-657, A672-679, and A819-831 had the highest editing efficiency with the longest deletion for each of their respective regions. Accordingly, these five variants were used for the following combinatorial deletion experiment discussed in Example 1 and shown in FIG. 5.Conclusions

[0216] This example demonstrates that prime editors can tolerate small 5-15 amino acid deletions within the Cas9 domain.

[0217] This example optimized five distinct deletions located in the REC2, REC3, and HNH domains of Cas9 that resulted in minimal loss in prime editing activity, finding that the optimal deletions were residue- specific and often spanned loops or loop-helix junctions. References1. Neumayr, L. D., Hoppe, C. C., & Brown, C. (2019). Sickle cell disease: current treatment and emerging therapies. Am J Manag Care, 25(18 Suppl), S335-S343.2. Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Maglott, D. R. (2016). ClinVar: public archive of interpretations of clinicallyrelevant variants. Nucleic Acids Res, 44(D1), D862-868.doi.org / 10.1093 / nar / gkv 12223. Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W.,Levy, J. M., Liu, D. R. (2019). Search-and-replace genome editing without73 / 155B1195.70213WO00#15140132v3double-strand breaks or donor DNA. Nature, 576(7785), 149-157. doi.org / 10.1038 / s41586-019-1711-44. Doman, J. L., Pandey, S., Neugebauer, M. E., An, M., Davis, J. R., Randolph,P. B., Liu, D. R. (2023). Phage-assisted evolution and protein engineeringyield compact, efficient prime editors. Cell, 186(18), 3983-4002e3926. doi.org / 10.1016 / j.cell.2023.07.0395. Sousa, A. A., Hemez, C., Lei, L., Traore, S., Kulhankova, K., Newby, G.A., Liu, D. R. (2025). Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells. NatBiomed Eng, 9(1), 7-21. doi.org / 10.1038 / s41551-024-01233-3SEQUENCESPrime Editors

[0218] In some embodiments, a prime editor sequence comprises the structure [nterm_linker] - [cas9_sequence] - [cterm_linker_rt]. In some embodiments, the [nterm_linker] corresponds to the sequence of SEQ ID NO: 13. In some embodiments, the [cterm_linker_rt] corresponds to the sequence of SEQ ID NO: 14. In some embodiments, the [cas9_sequence] corresponds to any one of the sequences disclosed in Table 2, below.nterm_linkerMKRTADGSEFESPKKKRKV (SEQ ID NO: 13)cterm_linker_rt SGGSSGGSKRTADGSEFESPKKKRKVSGGSSGGSISSSKHTLSQMNKVSNIVKEPELP DIYKEFKDITADTNTEKLPKPIKGLEFEVELTQENYRLPIRNYPLTPVKMQAMNDEIN QGLKGGIIRESKAINACPVIFVPRKEGTLRMVVDYRPLNKYVKPNVYPLPLIEQLLAKI QGSTIFTKLDLKSAYHQIRVRKGDEHKLAFRCPRGVFEYLVMPYGIKTAPAHFQYFIN TILGEAKESHVVCYMDDILIHSKSESEHVKHVKDVLQKLKNANLIINQAKCEFHQSQ VKFLGYHISEKGLTPCQENIDKVLQWKQPKNQKELRQFLGQVNYLRKFIPKTSQLTH PLNKLLKKDVRWKWTPTQTQAIENIKQCLVSPPVLRHFDFSKKILLETDVSDVAVGA VLSQKHDDDKYYPVGYYSAKMSKAQLNYSVSDKEMLAIIKSLEHWRHYLESTIEPF KILTDHRNLIGRITNESEPENKRLARWQLFLQDFNFEINYRPGSANHIADALSRIVDET EPIPKDNEDNSINFVNQISISGGSKRTADGSEFESPKKKRKVGSGPAAKRVKLD (SEQ ID NO: 14)PegRNA74 / 155B1195.70213WO00#15140132v3CUGUAUCUAUAUUCAUCAUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAG GCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUGGCACCAUU AAAGAAAAUAUCAUCUUUGGUGUGAGUUACGAUGAAUAUAGAUACGCGGUUC UAUCUAGUUACGCGUUAAACCAACUAGAA (SEQ ID NO: 15)Target DNA TGGCACCATTAAAGAAAATATCATTGGTGTTTCCTATGATGAATATAGATACAGA AGCGTCATC (SEQ ID NO: 16)Table 2. Cas9 Sequences for Prime Editors75 / 155B1195.70213WO00#15140132v376 / 155B1195.70213WO00 #15140132v377 / 155B1195.70213WO00 #15140132v378 / 155B1195.70213WO00 #15140132v379 / 155B1195.70213WO00 #15140132v380 / 155B1195.70213WO00 #15140132v381 / 155B1195.70213WO00 #15140132v382 / 155B1195.70213WO00 #15140132v383 / 155B1195.70213WO00 #15140132v384 / 155B1195.70213WO00 #15140132v385 / 155B1195.70213WO00 #15140132v386 / 155B1195.70213WO00 #15140132v387 / 155B1195.70213WO00 #15140132v388 / 155B1195.70213WO00 #15140132v389 / 155B1195.70213WO00 #15140132v390 / 155B1195.70213WO00 #15140132v391 / 155B1195.70213WO00 #15140132v392 / 155B1195.70213WO00 #15140132v393 / 155B1195.70213WO00 #15140132v394 / 155B1195.70213WO00 #15140132v395 / 155B1195.70213WO00 #15140132v396 / 155B1195.70213WO00 #15140132v397 / 155B1195.70213WO00 #15140132v398 / 155B1195.70213WO00 #15140132v399 / 155B1195.70213WO00 #15140132v3100 / 155B1195.70213WO00 #15140132v3101 / 155B1195.70213WO00 #15140132v3102 / 155B1195.70213WO00 #15140132v3103 / 155B1195.70213WO00 #15140132v3104 / 155B1195.70213WO00 #15140132v3105 / 155B1195.70213WO00 #15140132v3106 / 155B1195.70213WO00 #15140132v3107 / 155B1195.70213WO00 #15140132v3108 / 155B1195.70213WO00 #15140132v3109 / 155B1195.70213WO00 #15140132v3110 / 155B1195.70213WO00 #15140132v3111 / 155B1195.70213WO00 #15140132v3112 / 155B1195.70213WO00 #15140132v3113 / 155B1195.70213WO00 #15140132v3114 / 155B1195.70213WO00 #15140132v3115 / 155B1195.70213WO00 #15140132v3116 / 155B1195.70213WO00 #15140132v3117 / 155B1195.70213WO00 #15140132v3118 / 155B1195.70213WO00 #15140132v3119 / 155B1195.70213WO00 #15140132v3120 / 155B1195.70213WO00 #15140132v3121 / 155B1195.70213WO00 #15140132v3122 / 155B1195.70213WO00 #15140132v3123 / 155B1195.70213WO00 #15140132v3124 / 155B1195.70213WO00 #15140132v3125 / 155B1195.70213WO00 #15140132v3126 / 155B1195.70213WO00 #15140132v3127 / 155B1195.70213WO00 #15140132v3128 / 155B1195.70213WO00 #15140132v3129 / 155B1195.70213WO00 #15140132v3130 / 155B1195.70213WO00 #15140132v3131 / 155B1195.70213WO00 #15140132v3132 / 155B1195.70213WO00 #15140132v3133 / 155B1195.70213WO00 #15140132v3134 / 155B1195.70213WO00 #15140132v3135 / 155B1195.70213WO00 #15140132v3136 / 155B1195.70213WO00 #15140132v3137 / 155B1195.70213WO00 #15140132v3Base editors

[0219] In some embodiments, a base editor sequence comprises the structure [nterm_linker_TadDE_linker] - [cas9_sequence] - [cterm_linker_ugi_nls]. In some embodiments, the [nterm_linker_TadDE_linker] corresponds to the sequence of SEQ ID NO: 17. In some embodiments, the [cterm_linker_ugi_nls] corresponds to the sequence of SEQ ID NO: 18. In some embodiments, the [cas9_sequence] corresponds to any one of the sequences disclosed in Table 3, below.nterm_linker_T adDE_linker MKRTADGSEFESPKKKRKVSSEVEFSHEYWMRHALTLAKRARDEGEAPVGAVLVL NNRVIGEGWVRRIGLHDPTAHAEIMALRQGGLVMQNPRLIDATLYVTFEPCVMCAG AMINSRIGRVVFGVRNSKRGAAGSLMNVLNYPGMNHRVEITEGILADECAALLCDF YRMPRQVFNAQKKAQSSINSGGSSGGSSGSETPGTSESATPESSGGSSGGS (SEQ ID NO: 17)138 / 155B1195.70213WO00#15140132v3cterm_linker_ugi_nls SGGSGGSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDEST DENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSKRTADGSEFEPKKKRKV(SEQID NO: 18)sg_rna GGGGGCAGCCGAUACCCGGGGGUUUUAGUACUCUGGAAACAGAAUCUACUAA AACAAGGCAAAAUGCCGUGUUUAUCUCGUCAACUUGUUGGCGAGA (SEQ ID NO: 19)Table 3. Cas9 Sequences for Base Editors139 / 155B1195.70213WO00#15140132v3140 / 155B1195.70213WO00 #15140132v3141 / 155B1195.70213WO00 #15140132v3142 / 155B1195.70213WO00 #15140132v3143 / 155B1195.70213WO00 #15140132v3144 / 155B1195.70213WO00 #15140132v3EQUIVALENTS AND SCOPE

[0220] In the articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Embodiments or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.145 / 155B1195.70213WO00#15140132v3

[0221] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claims that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is / are referred to as comprising particular elements and / or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and / or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0222] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the embodiments. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any embodiment, for any reason, whether or not related to the existence of prior art.

[0223] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended embodiments. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following embodiments.146 / 155B1195.70213WO00#15140132v3

Claims

CLAIMSWhat is claimed is:

1. A minimized Streptococcus pyogenes Cas9 (SpCas9) protein comprising a deletion of amino acid residues 172-176, 172-182, 173-177, 174-178, 175-179, 176-180, 177-181, 172-182, 174-188, 209-214, 211-216, 213-218, 646-657, 646-649, 647-650, 648-651, 668-675, 670-677, 671-677, 672-679, 673-680, 818-830, or 819-831 relative to an SpCas9 protein comprising an amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 10.

2. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 172-176.

3. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 172-182.

4. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 173-177.

5. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 174-178.

6. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 175-179.

7. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 176-180.

8. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 177-181.147 / 155B1195.70213WO00#15140132v39. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 172-182.

10. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 174-188.

11. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 209-214.

12. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 211-216.

13. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 213-218.

14. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 646-657.

15. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 646-649.

16. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 647-650.

17. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 648-651.

18. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 668-675.

19. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 670-677.148 / 155B1195.70213WO00#15140132v320. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 671-677.

21. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 672-679.

22. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 673-680.

23. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 818-830.

24. The minimized SpCas9 protein of claim 1, wherein the minimized SpCas9 protein comprises a deletion of amino acid residues 819-831.

25. A fusion protein comprising a minimized SpCas9 protein of any one of claims 1-24 and a nucleobase modifying enzyme.

26. The fusion protein of claim 25, wherein the nucleobase modifying enzyme is a reverse transcriptase.

27. The fusion protein of claim 26, wherein the nucleobase modifying enzyme is a deaminase.

28. The fusion protein of claim 27, wherein the deaminase is a cytidine deaminase.

29. The fusion protein of claim 27, wherein the deaminase is an adenosine deaminase.

30. A prime editor comprising a Cas9 domain having an amino acid sequence of any one of SEQ ID NOs: 20-174, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any one of SEQ ID NOs: 20-174.149 / 155B1195.70213WO00#15140132v331. The fusion protein of claim 26, wherein the reverse transcriptase comprises an amino acid sequence of any one of SEQ ID NOs: 2-5, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any one of SEQ ID NOs: 2-5.

32. A complex comprising the fusion protein of claim 25 and one or more guide RNAs.

33. The complex of claim 32, wherein the one or more guide RNAs includes a pegRNA.

34. The complex of claim 33, wherein the pegRNA is an engineered pegRNA.

35. A composition comprising a minimized SpCas9 protein of any one of claims 1-24, a fusion protein of any one of claims 25-29, a prime editor of claim 30 or 31, or a complex of any one of claims 32-34, and a guide RNA.

36. A polynucleotide encoding the minimized SpCas9 protein of any one of claims 1-24, a fusion protein of any one of claims 25-29, a prime editor of claim 30 or 31, or a complex of any one of claims 32-34, and a guide RNA.

37. A vector comprising the polynucleotide of claim 36.

38. The fusion protein of claim 25, wherein the fusion protein is a split fusion protein comprising an N-terminal portion and a C-terminal portion.

39. The fusion protein of claim 38, wherein the N-terminal portion comprises an N-intein, and the C-terminal portion comprises a C-intein.

40. A pharmaceutical composition comprising the minimized SpCas9 protein of any one of claims 1-24, the fusion protein of any one of claims 25-29, 38, and 39, the prime editor claim 30 or 31, the complex of any one of claims 32-34, the polynucleotide of claim 36, or the vector of claim 37, and a pharmaceutically acceptable excipient.

41. A cell comprising the minimized SpCas9 protein of any one of claims 1-24, the fusion protein of any one of claims 25-29, 38, and 39, the prime editor of claim 30 or 31, the 150 / 155B1195.70213WO00#15140132v3complex of any one of claims 32-34, the polynucleotide of claim 36, the vector of claim 37, or the pharmaceutical composition of claim 40.

42. A kit comprising the minimized SpCas9 protein of any one of claims 1-24, the fusion protein of any one of claims 25-29, 38, and 39, the prime editor of claim 30 or 31, the complex of any one of claims 32-34, the polynucleotide of claim 36, the vector of claim 37, or the pharmaceutical composition of claim 40.

43. A method of gene editing comprising contacting a target nucleic acid sequence with a fusion protein of any one of claims 25-29, 38, and 39 and a gRNA.

44. A method of base editing comprising contacting a target nucleic acid sequence with a fusion protein of any one of claims 27-29, 38, and 39 and a gRNA.

45. A method of prime editing comprising contacting a target nucleic acid sequence with a fusion protein of claim 26 and a pegRNA.

46. A minimized Staphylococcus auricularis Cas9 (“SauriCas9”) protein comprising a deletion of amino acid residues 1-3, 1-6, 125-132, 125-140, 128-135, 322-329, 725-766, 743-750, 1046-1061, or 1051-1061 relative to a SauriCas9 protein comprising an amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 11.

47. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 1-3.

48. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 1-6.

49. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 125-132.151 / 155B1195.70213WO00#15140132v350. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 125-140.

51. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 128-135.

52. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 322-329.

53. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 725-766.

54. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 743-750.

55. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 1046-1061.

56. The minimized SauriCas9 protein of claim 46, wherein the minimized SauriCas9 protein comprises a deletion of amino acid residues 1051-1061.

57. A fusion protein comprising a minimized SauriCas9 protein of any one of claims 46-56 and a nucleobase modifying enzyme.

58. The fusion protein of claim 57, wherein the nucleobase modifying enzyme of a reverse transcriptase.

59. The fusion protein of claim 57, wherein the nucleobase modifying enzyme is a deaminase.

60. The fusion protein of claim 59, wherein the deaminase is a cytidine deaminase.

61. The fusion protein of claim 59, wherein the deaminase is an adenosine deaminase.152 / 155B1195.70213WO00#15140132v362. A base editor comprising a Cas9 domain having an amino acid sequence of any one of SEQ ID NOs: 175-194, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any one of SEQ ID NOs: 175-194.

63. The base editor of claim 62, wherein the deaminase comprises an amino acid sequence of any deaminase in Table 1 or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with any deaminase in Table 1.

64. A complex comprising the fusion protein of any one of claims 57-61 and one or more guide RNAs.

65. A composition comprising a minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, a base editor of claim 62 or 63, or a complex of claim 64, and a guide RNA.

66. A polynucleotide encoding the minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, a base editor of claim 62 or 63, or a complex of claim 64, and a guide RNA.

67. A vector comprising the polynucleotide of claim 66.

68. The fusion protein of claim 57, wherein the fusion protein is a split fusion protein comprising an N-terminal portion and a C-terminal portion.

69. The fusion protein of claim 68, wherein the N-terminal portion comprises an N-intein, and the C-terminal portion comprises a C-intein.

70. A pharmaceutical composition comprising the minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, 68, and 69, a base editor of claim 62 or 63, a complex of claim 64, the polynucleotide of claim 66, or the vector of claim 67, and a pharmaceutically acceptable excipient.153 / 155B1195.70213WO00#15140132v371. A cell comprising the minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, 68, and 69, a base editor of claim 62 or 63, a complex of claim 64, the polynucleotide of claim 66, or the vector of claim 67, and a pharmaceutically acceptable excipient.

72. A kit comprising the minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, 68, and 69, a base editor of claim 62 or 63, a complex of claim 64, the polynucleotide of claim 66, or the vector of claim 67, and a pharmaceutically acceptable excipient.

73. A method of gene editing comprising contacting a target nucleic acid sequence with a fusion protein of any one of claims 57-61, 68, and 69 and a gRNA.

74. A method of base editing comprising contacting a target nucleic acid sequence with a fusion protein of any one of claims 57, 59-61, 68, and 69 and a gRNA.

75. A method of prime editing comprising contacting a target nucleic acid sequence with a fusion protein of claim 58 and a pegRNA.

76. An AAV comprising one or more polynucleotides encoding a minimized SpCas9 protein of any one of claims 1-24, a fusion protein of any one of claims 25-29, 38, and 39, a prime editor of claim 30 or 31, a complex of any one of claims 32-34, a minimized SauriCas9 protein of any one of claims 46-56, a fusion protein of any one of claims 57-61, 68, and 69, a base editor of claim 62 or 63, or a complex of claim 64.154 / 155B1195.70213WO00#15140132v3